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During puberty, adolescents achieve reproductive capability and attain adult 
height. An intact hypothalamic-pituitary-gonadal (HPG) axis is crucial for the 
normal onset of puberty. Pubertal timing is influenced by genetic and 
environmental factors such as nutrition and stress. However, the exact 
mechanisms that trigger puberty remain elusive. A recent finding of a paternally-
inherited loss-of-function mutation in MKRN3 gene in patients who were 
diagnosed with central precocious puberty suggests that key genes regulate the 
central restrain on the HPG axis during childhood, and that the loosening of the 
restrain precedes the onset of puberty. At the moment, the methods to measure 
the amount of the central restrain are limited to only observing its influence further 
down the HPG axis. Thus, a marker which reflects the strength of the central 
restrain directly could aid in the differential diagnosis and the follow-up of pubertal 
disorders. A variety of diseases can delay puberty, but it is particularly important 
to early identify the patients who suffer from acquired or congenital 
hypogonadotropic hypogonadism (CHH) which results from the absent or 
impaired functions of gonadotropin-releasing hormone. This congenital sex 
steroid deficiency predisposes to long-term consequences, but very little is known 
about its role in the modulation of growth during early infancy and its impact on 
health-related quality of life (HRQoL) in adulthood. 
In the first study, circulating MKRN3 levels were measured in boys with 
idiopathic short stature (ISS) (n=30) before and after the onset of puberty. Sixteen 
boys were treated with an aromatase inhibitor letrotzole (Lz) for two years in an 
attempt to increase their adult height. In boys, serum levels of MKRN3 declined 
faster before than after the clinical onset of puberty. The boys who were treated 
with Lz had a slower decrease in MKRN3 levels than placebo-treated boys, and 
the decline in MKRN3 had a reciprocal relationship with the clinical and the 
biochemical markers (i.e. testis size, luteinizing hormone, inhibin B, testosterone) 
of puberty onset. 
In the second study, the diagnoses that underlie delayed puberty (DP) and its 
outcome predictors were investigated in a large (n=244) series of patients who 
were examined for delayed puberty at the Helsinki University Central Hospital 
between 2004 and 2014. A multitude of different diagnoses were found to cause 
DP, albeit constitutional delay of growth puberty (CDGP) was the most common 
cause in both sexes. Further, annual growth velocity, a history of prior 
cryptorchidism, and a positive family history of DP were useful for the differential 
diagnosis of DP. Additionally, measuring testicular size with a ruler emerged as 
an effective parameter which could aid in differentiating the prepubertal boys with 
CHH from those with CDGP. 
The third and fourth study consisted of growth charts of 42 patients (36 boys 
and 6 girls) with CHH, and evaluated the influence of congenital sex steroid 
deficiency on growth from birth length to adult height. In girls with CHH and FGFR1 
mutations, the growth rate decreased from mid-childhood. Conversely, the boys 
with CHH experienced a length deflection during the first six months of life 
(minipuberty), which was likely to result from deficient testosterone surge during 
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the same period. In both sexes, the height standard deviation score nadir was 
reached at the age of pubertal induction. 
In the fifth study, the HRQoL was measured in men with CHH (n=30) with the 
generic 15D questionnaire. The men with CHH experienced an impaired HRQoL, 
especially in the dimensions of depression and distress. The finding that the age 
of diagnosis correlated negatively with HRQoL scores supports the view that 
timely diagnosis of CHH is an important goal when evaluating a patient with late 
puberty. 
In summary, sex steroids modulate growth from early infancy to adulthood. In 
boys, circulating MKRN3 levels decline before the clinical onset of puberty which 
supports the current view that MKRN3 is a key regulator of pubertal onset. Our 
findings suggest a relationship between estrogen and MKRN3 secretion. 
Additionally, the results pave the way for MKRN3 as a novel biochemical marker 
that may turn out to be useful in the evaluation of pubertal disorders in a research 
setting. Many diseases can delay pubertal maturation, but CDGP is the most 
common cause in Finland. In men, the timely diagnosis of CHH is crucial to avoid 
the long-term adverse effects of sex steroid deficiency on HRQoL. Finally, the 
results not only emphasize the importance of thorough review of medical history 
and a careful physical examination when evaluating an adolescent with DP, but 




FINNISH SUMMARY (TIIVISTELMÄ) 
Murrosiässä nuori siirtyy lapsuudesta aikuisuuteen saavuttaen sukukypsyyden ja 
aikuispituuden. Murrosiän ajoitukseen vaikuttaa mm. yleinen terveydentila, 
ravitsemus, stressi ja perimä. Murrosiän käynnistymisen ja etenemisen 
edellytyksenä on normaalisti toimiva hypotalamus-aivolisäke-sukupuolirauhanen-
järjestelmä. Sitä, mikä varsinaisesti käynnistää murrosiän, ei kuitenkaan tiedetä. 
Äskettäin julkaistu havainto, että isältä peritty MKRN3-geenin mutaatio altistaa 
ennenaikaiselle murrosiälle viittaa siihen, että lapsuusiän keskushermoston 
estovaikutus murrosiän käynnistymiseen johtuu osin puberteettia säätelevien 
geenien ilmentymisestä. Tällä hetkellä vain murrosiän käynnistymisen välillisiä 
vaikutuksia voidaan mitata verenkierrosta, mutta käytössä ei ole merkkiainetta, 
joka mittaisi suoraan keskushermoston estovaikutusta murrosiän käynnisty-
miseen. Tällainen merkkiaine voisi auttaa viivästyneen puberteetin erotusdiag-
nostiikassa ja puberteetin etenemisen arvioinnissa. Monet eri sairaudet voivat 
viivästyttää murrosikää, mutta erityisen tärkeää olisi löytää ajoissa potilaat, joilla 
viivästyneen puberteetin syynä on synnynnäinen hypogonadotrooppinen 
hypogonadismi (HH) eli aivolisäkkeen erittämien gonadotropiinien puutteesta 
johtuva sukupuolirauhasten vajaatoiminta. HH:n sukupuolihormonivaje altistaa 
hoitamatta pitkäaikaisille haittavaikutuksille, mutta sen vaikutuksista imeväisiän ja 
lapsuuden kasvuun sekä terveyteen liittyvään elämänlaatuun aikuisena tiedetään 
hyvin vähän. 
Tutkimuksen ensimmäisessä osakokonaisuudessa määritettiin seerumin 
MKRN3-tasot lyhytkasvuisilla pojilla puberteetin aikana. Osaa pojista hoidettiin 
kahden vuoden ajan aromataasin estäjä letrotsolilla aikuispituuden lisäämiseksi. 
Tulosten mukaan seerumin MKRN3-tasot laskevat voimakkaasti ennen murrosiän 
alkua sopien keskushermoston murrosiän estovaikutuksen määrän vähene-
miseen. MKRN3-tasojen laskuun liittyi myös murrosiän biokemiallisten 
merkkiaineiden (luteinisoiva hormoni, testosteroni, inhibiini B) nousu sekä 
puberteetin eteneminen. Letrotsoli-hoidetuilla todettiin ennen murrosiän käyn-
nistymistä hitaampi seerumin MKRN3-tasojen lasku kuin lumelääkettä saaneilla 
pojilla, viitaten siihen, että estrogeeni osallistuu murrosiän käynnistymisen 
säätelyyn. 
Tutkimuksen toisessa osakokonaisuudessa kartoitettiin viivästyneen 
puberteetin syyt Helsingin yliopistollisen keskussairaalan lastenendokrinologian 
vastaanotolla vuosien 2004–2014 aikana. Viivästyneen murrosiän taustalta löytyi 
30 eri diagnoosia, joista yleisin syy oli tuntemattomasta syystä viivästynyt 
murrosikä eli konstitutionaalinen viivästynyt murrosiän kehitys (CDGP). Tulokset 
osoittavat, että pituuskasvunopeus, aikaisemmin diagnosoitu piilokives ja 
lähisukulaisella todettu viivästynyt puberteetti auttavat viivästyneen murrosiän 
syiden erottelussa ja ennustavat murrosiän etenemistä. Lisäksi tulokset 
osoittavat, että synnynnäistä HH:ta sairastavilla esimurrosikäisillä pojilla kivesten 
koko on pienempi kuin CDGP-pojilla, ja että kivesten koon mittaaminen erottelee 
tehokkaasti HH:n ja CDGP:n toisistaan.  
Kolmas osakokonaisuus selvitti synnynnäisen HH:n vaikutuksia imeväisiän ja 
lapsuusiän kasvuun. Tutkimuksessa kuvattiin FGFR1-geenivirhettä kantavien 
synnynnäistä HH:ta sairastavien tyttöjen lapsuusiän kasvun piirteet. Heidän 
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pituuskasvunsa oli keskimäärin ikätovereita hitaampaa 4–7 vuoden iästä alkaen 
jatkuen aina sukupuolihormonihoidon aloitukseen asti. Vastaavasti HH-pojilla 
sukupuolihormonivaje assosioitui kasvun hidastumiseen jo minipuberteetin eli 
ensimmäisen puolen vuoden aikana, sekä johtaa myös murrosiän kasvu-
pyrähdyksen puuttumiseen. 
Tutkimuksen neljäs osakokonaisuus käsitteli synnynnäisen sukupuoli-
hormonivajeen vaikutusta terveyteen liittyvään elämänlaatuun aikuisiällä. HH-
miehillä todettiin 15D-elämänlaatumittarilla heikentynyt elämänlaatu aikuisena. 
HH-potilaiden varhaista tunnistamista puoltaa tutkimuksen havainto, että HH-
miehillä alentunut terveyteen liittyvä elämänlaatu assosioitui korkeampaan 
diagnoosi-ikään. 
Tutkimustulokset osoittavat, että sukupuolihormonit säätelevät kasvua jo 
imeväisiästä alkaen aina murrosiän päättymiseen asti. Pojilla MKRN3-tason lasku 
edeltää puberteetin käynnistymistä ilmentäen todennäköisesti keskushermoston 
murrosiän estovaikutuksen voimakkuutta. Tulokset tukevat tämänhetkistä 
käsitystä, että MKRN3-geenillä ja estrogeenillä on tärkeä osa murrosiän 
käynnistymisen säätelyssä. Ne myös luovat perustaa uusien puberteetin merkki-
aineiden löytymiselle ja niiden käytölle murrosiän häiriöiden tunnistamisessa. 
Moni sairaus hidastaa murrosiän käynnistymistä, mutta CDGP on yleisin 
yksittäinen syy puberteetin viivästymiseen Suomessa. HH:n tunnistaminen 
viivästyneen murrosiän taustalta on tärkeää, koska viivästynyt diagnoosi 
heikentää terveyteen liittyvää elämänlaatua jopa aikuisikään saakka. Tulokset 
korostavat esitietojen ja kattavan kliinisen tutkimuksen tärkeyttä selvitettäessä 




In 1977, the Nobel Prize in physiology was awarded to the scientists who 
discovered a small peptide, gonadotropin-releasing hormone (GnRH), secreted in 
brain (Burgus et al. 1971, Schally et al. 1971). The discovery of GnRH inspired 
further research which eventually led to the understanding of the basic functions 
and the genetic regulation of the hypothalamic-pituitary-gonadal (HPG) axis 
(Bennett et al. 1975, Blake et al. 1980, Mason et al. 1986, Franco et al. 1991, Lei 
& Rao 1994). Subsequently, gene mutations found in patients with congenital 
hypogonadotropic hypogonadism (CHH) and pubertal disorders have increased 
our understanding of the complex genetic control of puberty (Elks et al. 2010, 
Bianco & Kaiser 2009, Howard et al. 2016, Abreu et al. 2013). This was highlighted 
by the recent finding of a paternally inherited loss-of-function mutation in makorin 
ring finger protein 3 (MKRN3) gene in patients with central precocious puberty 
(CPP), which suggested that MKRN3 has a pivotal role in the inhibition of GnRH 
secretion (Abreu et al. 2013). Measuring circulating GnRH levels has been 
difficult, and observing the activity of GnRH neurons has been limited to 
measuring its effects further downstream on the HPG axis (i.e. gonadotropin and 
sex steroid levels). However, in girls circulating MKRN3 levels have shown 
promising results for serving as a direct marker of central restrain on GnRH 
neurons, whereas similar studies in boys have not been published (Hagen et al. 
2015).  
Before puberty, the HPG axis faces two prolonged activation periods. The first 
occurs during fetal life and the second activation right after birth. The levels of sex 
steroids start to increase after the first week of life, and reach adult-like levels at 
1 to 3 months of age, and then gradually decline by the age of 6 months (Forest 
et al. 1974, Winter et al. 1976, Bolton et al. 1989, Andersson et al. 1998, Kuiri-
Hanninen et al. 2011, Bergada et al. 2006). This minipuberty has been known for 
over 40 years (Forest et al. 1974, Winter et al. 1976), but its importance in human 
development and influence on growth remains unclear. After infancy, the HPG 
axis remains quiescent and under central restrain until it is reactivated at the onset 
of puberty.  
During puberty, adolescents achieve secondary sexual characteristics, 
experience growth spurt, and attain adult height. Thus, delayed pubertal 
maturation can cause low self-esteem and significant stress for adolescents and 
even limit their activities (Gross & Duke 1980). Delayed puberty (DP) is most 
commonly caused by constitutional delay of growth and puberty (CDGP) which is 
an idiopathic condition – an extreme end of the normal spectrum (Sedlmeyer & 
Palmert 2002). However, DP can also result from a variety of functional and 
chronic diseases. Patients with CHH have delayed or absent pubertal 
development, and CHH also serves as a practical model to investigate the long-
term impact of sex steroid deficiency (Sedlmeyer & Palmert 2002). The differential 
diagnosis of DP, especially between CDGP and CHH, can be challenging 
(Harrington & Palmert 2012). Therefore, physicians who evaluate patients with DP 
in school health care or at the pediatric outpatient clinic have a crucial role in the 
early identification of the patients with a pathological underlying cause of DP. 
Consequently, understanding the diagnoses that underlie DP and the predictors 
of its clinical course could lead to better patient care. 
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The aim of this study was to evaluate if circulating MKRN3 levels could serve 
as a read-out of the central restrain on the HPG axis in peripubertal boys, 
characterize the diagnoses that underlie DP, describe the childhood growth of 
CHH patients, especially length growth during minipuberty, and to evaluate the 




REVIEW OF THE LITERATURE 
1. HYPOTHALAMIC-PITUITARY-GONADAL (HPG) AXIS AND 
PUBERTY 
1.1. Current concepts on the development and function of GnRH 
neurons 
Normally functioning HPG axis has a critical role in the reproductive development. 
This neuroendocrinological cascade is initiated by GnRH neurons located in the 
hypothalamus. However, GnRH neurons rise from the olfactory placodes where 
they migrate towards the forebrain and the hypothalamus (Kim et al. 1999, Wray 
2010, Wierman, Kiseljak-Vassiliades & Tobet 2011). The sensitivity of this period 
is underlined by the fact that an impaired migration process results in congenital 
hypogonadism which clinically manifests in disorders of puberty in later life (Wray 
2010, Wierman, Kiseljak-Vassiliades & Tobet 2011, Boehm et al. 2015, Dwyer et 
al. 2015, Young 2012, Kallmann, Schonfeld & Barrera 1944, Valdes-Socin et al. 
2014, Legouis et al. 1991).  
1.1.1. The ontogeny and migration of GnRH neurons 
There is substantial evidence that GnRH neurons originate from the progenitor 
cells of the olfactory placodes of the developing embryo, whereas some have 
suggested that GnRH neurons arise from the neural crest (Kim et al. 1999, Wray 
2010, Schwanzel-Fukuda & Pfaff 1989, Wray, Grant & Gainer 1989, Forni et al. 
2011, Katoh et al. 2011). Nevertheless, these neurons are unique as they origin 
outside the central nervous system (CNS) and migrate towards the forebrain (Kim 
et al. 1999, Wray 2010, Schwanzel-Fukuda & Pfaff 1989). Based on studies in 
rodents, the migration pathway of GnRH neurons is marked by a variety of 
adhesion molecules (Bless et al. 2006, Garcia-Gonzalez et al. 2016), 
neurotransmitters (Casoni et al. 2012, Vastagh et al. 2015), and growth factors 
(Sabado et al. 2012, Chung & Tsai 2010). Initially, GnRH neurons attach to the 
axons of the vomeronasal-nerves (VNN) and climb towards the cribriform plate 
located at the nasal-forebrain junction. At the cribriform plate, GnRH neurons have 
to find their way caudally to the forebrain. Importantly, this phase reflects the close 
developmental relationship between the olfactory system and GnRH neurons, 
since an impaired GnRH migration at this stage results in a clinical syndrome of 
hypogonadotropic hypogonadism and anosmia (Kallmann syndrome, KS) (Boehm 
et al. 2015, Kallmann, Schonfeld &  Barrera 1944, Laitinen et al. 2011, Hutchins 
et al. 2016, Lewkowitz-Shpuntoff et al. 2012). After the cribriform plate, GnRH 
neurons continue their pathway to the forebrain until the migration ends at the 
hypothalamic area. At this point, GnRH neurons detach from the guidance of the 
VNN (Kim et al. 1999, Wray 2010, Schwanzel-Fukuda & Pfaff 1989). 
Subsequently, the neurons form extensions towards the anterior pituitary which 
enable the secretion of GnRH to the hypophyseal portal blood (Wierman, Kiseljak-
Vassiliades & Tobet 2011). At the anterior pituitary, GnRH regulates the secretion 
of gonadotropins which are critical for the normal development of gonads.  
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1.1.2. The composition and function of the GnRH pulse generator 
Anatomically, the GnRH pulse generator consists of a complex neuronal network 
which regulates the pulsatile secretion of GnRH and gonadotropins (Herbison 
2016, Piet et al. 2015). The hypothalamus receives a vast amount of intrinsic and 
environmental impulses. Subsequently, the information is filtered, processed, and 
transmitted onwards to the GnRH neurons through the adjacent neurons (Figure 
1A). These neurons secrete neuropeptides such as kisspeptin (Herbison 2016, 
Ward et al. 2009, Millar & Newton 2013). In humans, kisspeptin secreting neurons 
are located in the preoptic area and the arcuate nucleus of the hypothalamus 
(ARC). Kisspeptin activates the G protein-coupled receptor (GPR54)/kisspeptin-1 
receptor (KISS1R), and GnRH neurons are sensitive to kisspeptin and express 
KISS1R (Pinilla et al. 2012). In mice, the amount of kisspeptin sensitive GnRH 
neurons increase during peripuberty (Kallo et al. 2012). Kisspeptin stimulates 
GnRH secretion, and the administration of a kisspeptin analog to prepubertal mice 
induces the progression of puberty (Decourt et al. 2016). Conversely, an 
inactivating mutation in Kiss1 results in hypogonadism marked by the absence of 
puberty (Seminara et al. 2003). In humans, a loss-of-function mutation in KISS1 
is reported to cause CHH (Seminara et al. 2003), whereas activating mutations in 
KISS1 have been found in patients with CPP (Silveira et al. 2010). Most of the 
kisspeptin neurons secrete two co-transmitters: dynorphin (Dyn) and neurokinin B 
(NKB) (Skrapits et al. 2015). NKB and its receptor are encoded by tachykinin-3 
(TAC3) and its receptor (TACR3), respectively. In mice, an NKB analog induces 
GnRH activity and LH pulses through kisspeptin/gpr54 signaling (Grachev et al. 
2012). The administration of NKB alone does not appear to provoke gonadotropin 
secretion in humans, whereas administering it with kisspeptin increases LH 
secretion (Narayanaswamy et al. 2016). In support of the view that NKB stimulates 
GnRH secretion, a loss-of-function mutation in TAC3 or TACR3 results in 
congenital hypogonadotropism in humans (Topaloglu et al. 2012). Dynorphin 
synchronize and modulate the secretion of kisspeptin and transmit inhibitory 
signals to the GnRH neurons, thus in Dyn knockout mice gonadotropin secretion 
is compromised (Navarro et al. 2009). A subpopulation of kisspeptin neurons co-
secrete kisspeptin, NKB, and DYN, and are located in the ARC (Skrapits et al. 
2015). These neurons are called KNDy neurons, and they regulate the GnRH 
neurons (Figure 1A) (Pinilla et al. 2012). Gamma-amino butyric acid (GABA) 
influences on GnRH neurons through GABAA receptors (Watanabe, Fukuda & 
Nabekura 2014). Despite being an inhibitory neurotransmitter in the adult brain, in 
vivo studies suggest that GABA mediates excitatory impulses to GnRH neurons 
(Watanabe, Fukuda & Nabekura 2014). All in all, the intensity of transmitted 
signals to GnRH neurons determines whether the GnRH secretion is maintained 
at the basal amplitude or if the information is transmitted onwards in a form of 
altered GnRH secretion.  
GnRH is released into the pituitary portal blood with a diurnal pattern, 
particularly during the puberty onset (Rosenfield, Bordini & Yu 2013, Rosenfield, 
Bordini & Yu 2012, Albertsson-Wikland et al. 1997). An increase in GnRH 
secretion stimulates the anterior pituitary to secrete gonadotropins (i.e. luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH)). In women, LH is required 
in the induction of ovulation, and FSH for the maturation of the follicles in the 
ovaries (Simonneaux & Bahougne 2015). In men, FSH acts directly on the Sertoli 
cells, whereas LH stimulates androgen production in Leydig cells to promote 
spermatogenesis (O'Shaughnessy 2014, Huhtaniemi 2015). Additionally, the 
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testes secrete inhibin B which inhibits FSH secretion at the pituitary level (de 
Kretser et al. 2000, Andersson et al. 2004, Boepple et al. 2008, Sehested et al. 
2000), and anti-müllerian hormone (AMH) which is crucial for the development of 
sexual dimorphism as it induces the atrophy of the Müllerian ducts in male fetuses 




Figure 1. Panel A, The negative-feedback loop of the hypothalamic-pituitary-gonadal 
(HPG) axis after puberty. Gonadotropin-releasing hormone (GnRH) neurons secrete 
GnRH into the portal blood of anterior pituitary, which induces the secretion of 
gonadotropins. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) induce 
sex steroid production in the gonads. Sex steroids, especially estrogen, inhibit GnRH and 
gonadotropin secretion. At least a part of the feedback on GnRH neurons is mediated 
through kisspeptin, neurokinin B, and dynorphin. Panel B, the activity of the HPG axis 
from fetal life to adolescence (Pinilla et al. 2012, de Kretser et al. 2000, Kuiri-Hanninen, 
Sankilampi & Dunkel 2014, Jin & Yang 2014). 
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1.1.3. The activation phases of the HPG axis 
Before puberty, the HPG axis faces two activation periods (Figure 1B). The first 
takes place during fetal life when the levels of LH and FSH peak at the mid-
gestation (Kaplan & Grumbach 1976, Debieve et al. 2000). This hormonal surge 
is more pronounced in the female than in the male fetuses (Reyes, Winter & 
Faiman 1973, Clements et al. 1976). Thereafter, the levels of LH and FSH decline 
reaching only low levels at birth (Debieve et al. 2000). The second activation 
period occurs after birth. During the first 24 hours of life, there is a transient peak 
in LH secretion which resolves quickly (Corbier et al. 1990). Then, the HPG axis 
is reactivated at the age of one week and the active phase lasts for the next 6 to 
9 months (Forest et al. 1974, Winter et al. 1976, Kuiri-Hanninen, Sankilampi & 
Dunkel 2014). During this minipuberty, gonadotropin and sex steroid levels 
increase and reach adult-like levels at 1 to 3 months of age (Winter et al. 1976, 
Tapanainen et al. 1981, Andersson et al. 1998, Bergada et al. 2006, Kuiri-
Hanninen, Sankilampi & Dunkel 2014), and serum inhibin B and AMH levels surge 
concomitantly (Andersson et al. 1998, Aksglaede et al. 2010). However, the 
postnatal surge in hormonal levels differs between sexes. In boys, the 
gonadotropin response is LH dominant, whereas in girls FSH is more profoundly 
elevated (Bergada et al. 2006, Ibanez et al. 2002). Testosterone levels decline by 
6 months of age, but girls may still show elevated estradiol levels at 3-4 yrs of age 
(Kuiri-Hanninen et al. 2011).  
Estradiol levels fluctuate, whereas testosterone levels peak more sharply. 
Besides hormonal changes, maturing follicles can be detected in girls during 
minipuberty (Kuiri-Hanninen et al. 2013). In primates testis, the number of Sertoli 
cells increase from birth to infancy concomitantly with the elevated gonadotropin 
levels (Simorangkir, Marshall & Plant 2003), which suggests that minipuberty is 
important for the proliferation of Sertoli cells (Simorangkir, Marshall & Plant 2003). 
In support of this, boys with CHH may show normal genitalia at birth, but a 
progressive involution of the scrotum during minipuberty (Main, Schmidt & 
Skakkebaek 2000). At the same time, the number of germ cells, Sertoli cells and 
Leydig cells in healthy boys increase, and urinary prostate specific antigen levels 
are transiently elevated (Kuiri-Hanninen et al. 2011, Codesal et al. 1990, Muller & 
Skakkebaek 1984, Cortes, Muller & Skakkebaek 1987). However, the initiation of 
spermatogenesis is prevented by the absence of androgen receptors in Sertoli 
cells (Chemes et al. 2008). During the first six months, testicular and penis size 
increase (Kuiri-Hanninen et al. 2011, Boas et al. 2006). The hormonal minipuberty 
has been known for 40 years, but only recently some of its importance in human 
development has been understood. The early hormonal surge, especially 
testosterone, is associated with male-type behavior in both boys and girls 
(Lamminmaki et al. 2012). Low testosterone levels are associated with early 
phonological development and language organization in both sexes (Friederici et 
al. 2008, Quast et al. 2016).  
During childhood, the HPG axis remains quiescent under the central restrain 
with the exception of some overnight LH secretion (Mitamura et al. 2000, 
Mitamura et al. 1999, Apter et al. 1993, Wu et al. 1996). Despite of the gonadostat, 
the HPG axis remains functional since it can be evoked with a GnRH test which in 
prepubertal patients shows a small but a significant increase in LH levels and a 
considerable FSH response (Dickerman, Prager-Lewin & Laron 1979). The onset of 
puberty is preceded by the removal of the gonadostat which results in an 
increased amplitude and frequency of GnRH secretion (Herbison 2016, Oerter et 
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al. 1990). Subsequently, the levels of gonadotropins increase and stimulate sex 
steroids secretion which ultimately induce pubertal maturation (Oerter et al. 1990, 
Andersson et al. 1997).  
1.1.4. The regulation of the HPG axis 
After the onset of puberty the HPG axis is under the regulation of a negative-
feedback loop (Figure 1A). The role of estrogen in regulating GnRH secretion 
appears to be bipartite. Estrogen inhibits Kiss1 expression and gonadotropin 
secretion in mice, but there is evidence of a positive estrogen-kisspeptin feedback 
circuit as well (Dorling et al. 2003, Clarkson et al. 2010, Dubois et al. 2015, Dubois 
et al. 2016). In pubertal primates, the removal of circulating estrogen increases 
the secretion of kisspeptin, and the administration of estrogen restores the 
kisspeptin activity suggesting that estrogen is a crucial inhibitor of GnRH secretion 
(Kenealy et al. 2016, Kenealy et al. 2013). Testosterone also appear to regulate 
GnRH secretion, since a treatment with testosterone in castrated male monkeys 
suppresses LH and FSH secretion and the levels of kisspeptin mRNA in 
mediobasal hypothalamus (Shibata et al. 2007). Due to the aromatization of 
androgens into estrogens, the inhibitory effects of testosterone on the HPG axis 
are believed to be estrogen-mediated. The administration of estrogen decreases 
the LH secretion in both healthy men and men with isolated GnRH deficiency 
(Finkelstein et al. 1991), whereas the removal of the estrogen inhibition with an 
aromatase inhibitor (AI), which is a blocker of estrogen biosynthesis, results in 
increased levels of gonadotropins (Finkelstein et al. 1991, Hayes et al. 2000, 
Wickman & Dunkel 2001). Moreover, in late maturing boys who were treated 
simultaneously with an AI and testosterone, the levels of baseline gonadotropins 
and GnRH induced LH-response increased significantly, which further supports 
the key role of estrogen in the regulation of human puberty (Wickman & Dunkel 
2001). 
1.2. Normal puberty 
1.2.1. General concepts 
During puberty, the adolescent achieves secondary sexual characteristics and 
reproductive capability, and eventually attains adult height. During the last 
century, the timing of puberty has declined rapidly until the 1950s, and, thereafter, 
the decrease has shown a steadier phase (Euling et al. 2008). The onset of 
puberty is marked by the development of glandular breast tissue in girls and an 
increase in testicular volume in boys (Marshall & Tanner 1969, Marshall & Tanner 
1970). Timing of puberty shows large individual variation. Puberty may begin too 
early or it can be delayed. In Finland, all adolescents are screened for abnormal 
pubertal maturation at the age of 13 to 14 yrs in the school health care. 
1.2.2. Normal variation in the timing of puberty and secular trends 
Puberty onset normally occurs in boys at the average age of 11 to 12 yrs, but can 
vary from 9 to 14 yrs (Marshall & Tanner 1970, Ojajärvi 1982), whereas in girls, 
puberty begins at an average age of 10 to 11 yrs, but is still considered normal if 
glandular breast tissue (Tanner B2 starge) is found between 8 to 13 yrs of age 
(Marshall & Tanner 1969, Ojajärvi 1982). Another difference between the sexes 
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is observed in bone maturation. The onset of puberty occurs at a mean bone age 
of 11.1 years in girls and 11.7 years in boys (Marshall 1974). 
The decline in the age of pubertal timing has been biphasic. The age of 
menarche decreased gradually until the 1950s, and then the decline has 
plateaued as a result of better nutrition, hygiene, and diet (Sorensen et al. 2012). 
During the last two decades, several studies have investigated pubertal timing, 
and a trend towards an earlier puberty in girls has been reported both in the US 
and Europe (Sun et al. 2002, Aksglaede et al. 2009, Biro et al. 2013). However, 
the results of the studies are inconsistent. Studies over longer period of time failed 
to show a decline in the age of puberty onset during the last 20 yrs, which 
suggested a difference in the timing of puberty between the US and Europe (Juul 
et al. 2006, Mul et al. 2001). The Copenhagen puberty study reported a decline in 
the age of thelarche from 10.9 to 9.9 yrs during a period of 15 yrs, but the decrease 
in the age of thelarche was not as significant as reported in the US (Sun et al. 
2002, Aksglaede et al. 2009, Wu, Mendola &  Buck 2002). Further, the decline in 
the timing of puberty was not supported by a change in the biochemical markers 
of puberty (Aksglaede et al. 2009). The levels of gonadotropins and estrogen did 
not increase in parallel to the decrease in the age of thelarche, which pointed 
towards the earlier appearance of glandular breast tissues independent of 
gonadotropin secretion (Aksglaede et al. 2009). The age at menarche appears to 
decline. A recent study reported a trend towards an earlier age of thelarche, and 
also an earlier menarche in daughters than their mothers (Wohlfahrt-Veje et al. 
2016). The age at menarche in mothers correlate with the age at menarche in 
daughters, and similarly the pubertal timing of mothers and fathers influence on 
the age of puberty onset of their sons and daughters (Wohlfahrt-Veje et al. 2016, 
Ersoy et al. 2005). Thus, the timing of puberty appears to be parentally inherited. 
1.2.3. Clinical and biochemical markers of puberty  
Pubertal progress is categorized by using the Tanner stage classification which 
divides the development of the testes, breasts, and pubic hair into five categories 
(Marshall & Tanner 1969, Marshall & Tanner 1970). In boys, prepubertal genitals 
are categorized into genital stage 1 (G1), and when puberty is complete, the 
genital stage is 5 (G5) (Marshall & Tanner 1970). Similarly, in girls, the pubertal 
progression is classified from breast stage 1 to 5 (B1-B5) (Marshall & Tanner 
1969).  
In boys, a testis size more than 3 mL is widely used to indicate the clinical onset 
of puberty, whereas some studies have suggested that testicular volume of 4 mL 
marks the activation of the HPG axis (Sadov et al. 2016, Joustra et al. 2015, 
Ankarberg-Lindgren & Norjavaara 2004). Correspondingly, the appearance of 
glandular breast tissue (thelarche) (B2) indicates the clinical onset of puberty in 
girls (Marshall & Tanner 1969, Ojajärvi 1982).  
Tanner genital stage is a simple and the most widely used clinical assessment 
of the clinical onset and progression of puberty. However, it relies solely on the 
visual estimate of the breast, the genital, and the pubic hair stage. In boys, 
measuring the length and the width of the testes is an accurate method to estimate 
testicular volume. Several formulas have been used to estimate testis size, one of 
which is the Hansen formula: (mL) is length (cm) x width2 (cm) x 0.52 (Behre, 
Nashan & Nieschlag 1989). Another method used widely in clinical practice to 
determine testis size is the Prader orchidometry (Prader 1966). Testicular size can 
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be also measured with ultrasound (Diamond et al. 2000), but its usefulness is 
limited by costs and availability. Additionally, none of the three measuring 
methods is superior to the others in accuracy (Taskinen, Taavitsainen & Wikstrom 
1996). In girls, evaluating the presence of breast tissue can be very difficult, 
especially in an obese subject. In unclear cases, breast tissues can be determined 
by using the ultrasound (Garcia et al. 2000).  
Biochemical markers of puberty illustrate the activity of the HPG axis at the 
pituitary and at the gonadal level. A single measurement of LH or FSH represent 
indirectly the GnRH secretion. Additionally, the activity of the HPG axis can be 
assessed with two stress-tests. In a human chorionic gonadotropin (hCG) test, 
gonadal testosterone secretion is stimulated with hCG (Segal et al. 2009, Osuna, 
Arata-Bellabarba & Tortolero 2001), whereas in a GnRH test, LH and FSH 
releases are augmented by administering a GnRH analog (Rosenfield, Bordini &  
Yu 2013, Rosenfield, Bordini & Yu 2012, Dunkel et al. 1985). At gonadal level, the 
Sertoli cells inside the seminiferous tubules of the testes secrete inhibin B which 
can be used in the biochemical evaluation of puberty. However, the measurement 
of low inhibin B levels is subject to a high variation (Kalra et al. 2010). Another 
Sertoli cell origin peptide, AMH, has been reported in studies addressing pubertal 
disorders. Serum AMH levels declined during puberty which reflected the 
gonadotropin influence on the Sertoli cell maturation (Hero et al. 2012). Moreover, 
inhibin B and AMH levels have been suggested to discriminate between the boys 
with idiopathic pubertal delay and CHH (Coutant et al. 2010, Adan et al. 2010). 
1.2.4. Molecular genetic basis of puberty  
During the last 30 yrs, the discovery of novel genes in patients with pubertal 
disorders, especially CHH, has revealed the genetic complexity of human puberty 
(Elks et al. 2010, Bianco & Kaiser 2009, Boehm et al. 2015). In the past, the genes 
associated with CHH were discovered by identifying single candidate CHH genes 
and linking them to the phenotypic features of CHH (Pitteloud et al. 2006, Dode 
et al. 2003, Dode et al. 2006). Additionally, depicting the pedigrees of CHH 
patients has been fruitful in identifying new candidate genes and revealing the low 
penetrance for most of the CHH genes (Gurbuz et al. 2012). By using these 
methods approximately 30 to 35% of genes that underlie CHH have been 
discovered (Crowley 2011), which suggests that many patients with CHH are 
currently without a genetic diagnosis. Recently, new methods such as next-
generation sequencing, proteomics, and genomics have yielded additional 
precision in finding novel CHH genes. The problem in identifying causative CHH 
genes lies in the absence of consensus of validation standards (MacArthur et al. 
2014). However, whole-genome sequencing and its implications are likely to 
reveal the remaining portion of unknown CHH genes in the near future (Stamou, 
Cox & Crowley 2015). 
Very recent discoveries of genes that underlie delayed and precocious puberty 
have increased our knowledge on the genetic control of human puberty. A loss-
of-function mutation in MKRN3 was discovered in patients with CPP (Abreu et al. 
2013). Subsequently, circulating MKRN3 levels were measured in girls before and 
after the onset of puberty (Hagen et al. 2015). These findings suggested that a 
normally functioning MKRN3 is critical for maintaining the central inhibition on the 
GnRH neurons. MKRN3 is expressed widely in human tissues, and is a putative 
E3 ubiquitin ligase, but its exact mechanisms are unclear (reviewed in Abreu et 
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al. 2015). Very recently, a pathologic mutation in immunoglobulin superfamily 
member 10 (IGSF10) gene was found in six unrelated Finnish families with late 
puberty (Howard et al. 2016). Apparently, these genes control the timing of 
puberty, but, at the same time, they represent only a fraction of potential puberty 
genes that are yet to be found. 
The knowledge of genetic regulation of puberty stems mainly from the 
mutations found in patients with CHH. The most common genes that are found 
mutated in CHH patients, especially the ones reported in Finnish patients, are 
listed in Table 1 (Table 1). In brief, CHH genes regulate GnRH neuron migration 
and development or GnRH secretion and action (Table 1). The inheritance pattern 
differs between CHH genes, for example, anosmin 1 (ANOS1) is located in 
chromosome X, thus mutations in ANOS1 manifest commonly in male CHH 
patients (Boehm et al. 2015). Remarkably, only less than 10% of CHH cases have 
a molecular genetic verification of CHH (Boehm et al. 2015). In Finland, the most 
common mutated CHH gene is fibroblast growth factor receptor 1 (FGFR1). In 
fact, one third of the Finnish patients with CHH carry a mutation in FGRF1 
(Laitinen et al. 2011). Further, FGFR1 mutations manifest with skeletal anomalies 
and, at a population level, are suggested to be associated with childhood obesity 
(Jiao et al. 2011, Costa-Barbosa et al. 2013), whereas ANOS1 associates with a 
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1.3. Delayed puberty (DP) 
The majority of adolescents enter puberty within the normal age range. However, 
sometimes pubertal maturation occurs later than expected. Delayed puberty is 
defined as the absence of clinical signs of puberty at the age of 2 to 2.5 standard 
deviation (SD) above the mean age of the general population, and it affects 
approximately 2% of adolescents (Marshall & Tanner 1969, Marshall & Tanner 
1970, Lee 1980). Delayed puberty is caused by a variety of conditions (Sedlmeyer 
& Palmert 2002, Reindollar & McDonough 1981, Lawaetz et al. 2015). The most 
common cause is constitutional delay of growth and puberty (CDGP) which 
constitutes up to 65% of cases with DP at a single pediatric endocrinology 
outpatient clinic (Sedlmeyer & Palmert 2002). On the other hand, DP can be 
caused by chronic diseases and pathological entities, such as craniopharyngioma 
and Crohn’s disease, which need to be diagnosed and treated as early as 
possible. This emphasizes the key role of first-line evaluation in identifying these 
patients early in school health care and referring them onwards to the pediatric 
outpatient clinic. 
1.3.1. Diagnostic criteria in Finland 
Due to the secular trend in the timing of puberty, the diagnostic criteria of DP show 
variation between countries. Since two different testicular sizes have used to 
describe the clinical onset of puberty, the diagnostic criteria are not uniform either. 
In Finland, the age limits for precocious and delayed puberty was recently updated 
by an expert consensus (Raivio 2013). Consequently, a boy is considered to have 
DP if he is prepubertal (i.e. the pubertal stage G1 and/or testis volume less than 
3 mL) at the age of 13.5–14 yrs (Ojajärvi 1982), and in a girl if she is at the B1 
stage at the age of 13.0 or more (Ojajärvi 1982).  
1.3.2. Underlying causes 
The most frequent cause of DP is CDGP which is an extreme end of normal 
variation (Sedlmeyer & Palmert 2002, Clayton et al. 1988). Thus, CDGP is an 
idiopathic condition which is often inherited, since up to 65% of the first degree 
relatives of CDGP patients report a history of DP (Sedlmeyer & Palmert 2002). 
However, a family history of DP is not pathognomonic to CDGP as late maturation 
is also found among the close relatives of patients with CHH (Sedlmeyer & 
Palmert 2002). The diagnosis of CDGP is set after the pathological causes of DP 
are ruled out. The other diagnoses can be classified into three categories. Patients 
with permanent hypogonadotropic hypogonadism (PHH) have low gonadotropin 
and sex steroid levels that result from a pathology in the CNS or a permanent 
disease that delays puberty. Importantly, CHH constitutes the majority of cases 
with PHH (Sedlmeyer & Palmert 2002). Similarly, functional hypogonadotropic 
hypogonadism (FHH) category consists of patients who have low gonadotropin 
and sex steroid levels but do not have any biochemical and clinical signs that 
would suggest the presence of a permanent cause of DP and an identified 
disease, such as celiac disease that is likely to delay maturation (Sedlmeyer & 
Palmert 2002). Finally, high basal gonadotropin levels and gonadal failure is 
characteristic to patients with hypergonadotropic hypogonadism (Hyper H). The 
frequency and distribution of the four diagnostic categories of DP at a pediatric 
outpatient clinic of a single tertiary center is presented in Figure 4 (Figure 2).  
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Figure 2. The frequency of causes that underlie delayed puberty in boys (A) and 
in girls (B) evaluated in a single tertiary center. Modified from Sedlmeyer et al. 
(Sedlmeyer & Palmert 2002). CDGP, Constitutional delay of growth and puberty; 
PHH, permanent hypogonadotropic hypogonadism; FHH, functional 
hypogonadotropic hypogonadism; Hyper H, hypergonadotropic hypogonadism. 
 
1.3.3. Evaluation of patient with DP 
The evaluation of DP includes a careful clinical examination and a review of the 
medical history. A history of undescended testes (i.e. cryptorchidism), micropenis, 
anosmia/hyposmia, and prior infertility treatments in close relatives are clinical 
cues that increase the risk for permanent hypogonadism (reviewed in Bouvattier 
et al. 2011). History of headache and other neuro-ophthalmic symptoms should 
be screened as well (Taylor et al. 2012). Subsequently, adolescents who present 
with the above medical history or signs and symptoms that raise a suspicion of 
pathologic cause of DP should be referred to the pediatric outpatient clinic for 
further investigation. 
The diagnostic process of DP is categorized into the first and second-line 
investigations (Palmert & Dunkel 2012). The first-line investigations include the 
evaluation of genital and pubic hair stage, determining the annual growth velocity 
and bone age, measuring baseline sex steroid and gonadotropin levels, and 
biochemical analyses (e.g. thyrotropin, free thyroxine, and creatine) to rule out 
chronic diseases such as hypothyroidism or celiac disease (Palmert & Dunkel 
2012). High basal LH and FSH levels easily identify patients with Hyper H (Abitbol, 
Zborovski & Palmert 2016). Sex steroid levels can be used in predicting the 
progress of puberty. In a previous study, 75% of boys with testosterone level 
above 0.7 nmol/L entered puberty within the next 12 months, and everyone within 
the next 15 months (Wu et al. 1993). Gonadotropin, estradiol, and testosterone 
levels show diurnal variation during puberty. After the onset of puberty, LH 
secretion increases during the day, whereas the diurnal secretion of FSH is less 
prominent (Albertsson-Wikland et al. 1997, Mitamura et al. 1999, Goji & Tanikaze 
1993). Testosterone secretion is induced during the night before the clinical onset 
of puberty, and thereafter the levels of testosterone increase both during day and 
night (Albertsson-Wikland et al. 1997, Mitamura et al. 1999, Goji & Tanikaze 
1993). The circadian rhythm of the estradiol is similar to that of testosterone 
(Mitamura et al. 2000).  
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During puberty, the gradual increase in sex steroid levels, especially estrogen, 
induces skeletal maturation. A delay in the onset of puberty results in a deviation 
also in the bone age. Thus, a patient with DP has a bone age which is 
approximately 2 to 3 yrs behind the calendar age (Lawaetz et al. 2015). 
Additionally, the absence of sex steroid-induced growth spurt can be visualized in 
the growth curve (Figure 3). The adolescents with DP continue to grow with the 
childhood growth velocity, whereas the height velocity of their peers rapidly 
increases. This results in a “dip” seen in the growth curve (Figure 3). Importantly, 
being shorter than their peers may be one of the reasons why patients with DP, 
especially boys, suffer from psychosocial burden (Gross & Duke 1980, Palmert & 
Dunkel 2012). Half of the boys with CDGP experience a decrease in height 
velocity already during childhood (Wehkalampi et al. 2007). In adolescence, a very 
slow height velocity (< 2 cm/yr), especially in a combination with neuro-ophthalmic 
symptoms, increases the risk for chronic diseases and panhypopituitarism (Taylor 
et al. 2012). However, only limited evidence of height velocity’s discrimination 
between the four diagnostic categories of DP exists (i.e. CDGP, PHH, FHH, and 
Hyper H) (Palmert & Dunkel 2012).  
In some cases, the first-line investigations of DP cannot provide sufficient 
information to rule out the pathological causes of DP. Thus, the second-line 
investigations offer more precise information about the HPG axis. The studies 
include GnRH and hCG stress testing, a brain MRI, and the markers of Sertoli cell 
function, and genetic testing (reviewed in Palmert & Dunkel 2012). The 
performance of inhibin B and AMH together with GnRH and hCG tests in the 
differential diagnosis of DP (i.e. CDGP vs CHH) is discussed in detail below. A 
brain MRI scan is performed in cases where the clinician suspects that pubertal 
delay might be caused by CHH, or a lesion in the CNS, or requires the 
visualization of the olfactory or inner ear structures (i.e. suspicion of CHH) 
(Lewkowitz-Shpuntoff et al. 2012). 
 
 
Figure 3. A typical growth curve, mid-parental target height (MPH) 
(asterisk), and predicted adult height (vertical line) of a boy with 
constitutional delay of growth and puberty (CDGP) who received 
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1.3.4. Treatment 
Before hormonal induction of puberty, the pathologic causes of DP must be 
excluded with a sufficient probability (Palmert & Dunkel 2012). The patients with 
CDGP have two treatment options: sex steroid treatment or watchful waiting 
(Dunkel & Quinton 2014). The onset of puberty can be waited with a careful follow-
up (Dunkel & Quinton 2014). However, the absence of puberty can cause 
significant psychosocial stress for the adolescent (Gross & Duke 1980), which 
supports the induction of puberty (Palmert & Dunkel 2012). The treatment of DP 
(girls with estrogen gel and boys with low-dose intramuscular testosterone in 
Finland) intends to induce sexual maturation and an increased growth velocity, 
and appears to affect positively on self-esteem (Figure 3) (Soliman, Khadir & 
Asfour 1995, Bergada & Bergada 1995, Kaplowitz 1998). 
Usually, estrogen gel is administered with gradually increasing amounts, and 
the response is evaluated at the follow-up visits (Wehkalampi et al. 2011, 
Ankarberg-Lindgren, Kristrom & Norjavaara 2014). The concept of starting the 
treatment with low estrogen doses stem from the idea of mimicking the normal 
puberty. Indeed, at early puberty low estrogen levels promote growth, whereas a 
higher level that occurs late in puberty is required to complete the physical 
development (Albin et al. 2012). Low-dose testosterone treatment is well-tolerated 
and has relatively few adverse effects, but the dosage and the treatment period 
vary within and between countries (Palmert & Dunkel 2012, Ambler 2009). Ideally, 
the hormonal treatment of DP should result in the activation of the HPG axis. 
Currently, this may not be the case with boys who are treated with intra muscular 
testosterone, because low-dose testosterone treatment suppresses gonadotropin 
and testosterone secretion (Soliman, Khadir & Asfour 1995, Dunkel & Wickman 
2001). Testosterone is aromatized into estrogens which mediate the negative 
feedback to the hypothalamic and the pituitary levels of the HPG axis (Figure 1A) 
(Dunkel & Wickman 2001). Removing the negative feedback of estrogen is a 
potential novel treatment modality for DP (reviewed in Palmert & Dunkel 2012). 
Aromatase inhibitor letrozole increases gonadotropin and testosterone levels 
during peripuberty (Hero, Norjavaara & Dunkel 2005), which suggests that it also 
augments the progression of puberty. On the other hand, the impact of AIs on 
bone health remains unclear (Hero et al. 2010, Hero 2016). A well-designed 
randomized controlled study on the use of AI for the treatment of DP is definitely 
required (Palmert & Dunkel 2012). The treatment of DP should always include a 
follow-up to ensure the normal progression of puberty, and the absence or 
deceleration of the tempo of puberty and growth during the follow-up should raise 
the suspicion of a pathologic cause of DP, even though the initial diagnostic work-
up resulted in the diagnosis of CDGP.  
1.4. Congenital hypogonadotropic hypogonadism (CHH) 
Congenital hypogonadotropic hypogonadism is a rare reproductive disorder which 
is caused by an impaired secretion, production, or action of GnRH (Boehm et al. 
2015, de Roux et al. 1997, Bouligand et al. 2009). When hypogonadotropism is 
accompanied by anosmia or hyposmia, it is called Kallmann syndrome (KS). KS 
affects approximately 1:48000 live births in Finland (Laitinen et al. 2011). The 
patients with most severe CHH suffer from sex steroid deficiency throughout their 
life, starting from fetal life when the deficiency may manifest in cryptorchidism or 
micropenis, and result in an absent or incomplete puberty in adolescence (Main, 
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Schmidt & Skakkebaek 2000, Grumbach 2005, Dwyer, Jayasena & Quinton 
2016). In some cases, patients with CHH may experience a reversal of 
hypogonadism later in life. In fact, the reversal variants constitute up to 18% of 
CHH cases, and the reversal of hypogonadism occurs despite of partial or absent 
puberty (Raivio et al. 2007, Sidhoum et al. 2014). The objectives in treating a CHH 
patient are to achieve secondary sexual characteristics and fertility, and induce 
linear growth and bone maturation (Boehm et al. 2015). The long-term health 
effects of CHH include an increased risk for osteoporosis (Laitinen et al. 2012a, 
Behre et al. 1997), metabolic diseases (Zarotsky et al. 2014), and impaired health-
related quality of life (Aydogan et al. 2012, Shiraishi, Oka & Matsuyama 2014). 
Consequently, this underpins the importance of the appropriate timing of 
diagnosis and early treatment initiation. 
1.4.1. Diagnostic criteria 
The classical diagnostic criteria of CHH include an absent or incomplete puberty 
at the age of 18 years, low sex steroid levels with normal or subnormal 
gonadotropin levels, and otherwise normal anterior pituitary function, and no 
organic cause for the condition (Raivio et al. 2009, Villanueva et al. 2015, Shaw 
et al. 2011). Thus, excluding other causes of permanent hypogonadism, such as 
craniopharyngioma, is essential for the diagnosis of CHH. Although these 
diagnostic criteria are widely used, there is a lack of international diagnostic 
criteria for CHH (Boehm et al. 2015).  
1.4.2. Clinical and biochemical evaluation  
The diagnosis of CHH is typically made during late adolescence or early 
adulthood. To discriminate patients with CHH from those with CDGP before 
puberty may be extremely difficult, and diagnosing CHH without genital anomalies 
during childhood or infancy is even more challenging (Dwyer, Jayasena &  
Quinton 2016). The same clinical and biochemical markers as in the evaluation of 
patients with DP are used in the diagnostic process of CHH. Additionally, a brain 
MRI is used to exclude lesions in the CNS and to visualize the olfactory bulbs and 
the inner ear (Della Valle et al. 2013). Ultrasonography of abdomen and pelvis 
can reveal renal agenesis and visualize the reproductive organs (ovaries, uterus, 
and testis). Since sex steroids are critical for normal pubertal growth spurt and the 
accumulation of bone mineral content, patients with CHH have an increased risk 
for osteoporosis (Laitinen et al. 2012a). The bone density is typically assessed 
with the dual-energy X-ray absorptiometry (DXA).  
The recent advances in molecular genetic testing have implemented the 
genetic testing of CHH into the diagnostic process of CHH. Molecular genetic 
testing is performed in order to find the inheritance pattern and the penetrance of 
the disease in the family (reviewed in Boehm et al. 2015, Pitteloud et al. 2010). 
Non-reproductive phenotype may be used in selecting patients to be screened for 
CHH genes. In fact, bony anomalies and dental agenesia are enriched in CHH 
patients with FGFR1 mutations (Costa-Barbosa et al. 2013, Zenaty et al. 2006), 
whereas mutations on ANOS1 are associated with a more severe reproductive 
phenotype and an increased prevalence of synkinesia (i.e. mirror movements) of 
the upper extremities (Salenave et al. 2008). In Finnish CHH patients, an 
algorithm which uses the non-reproductive phenotype can be used to guide the 
molecular genetic testing (Laitinen 2012). Genetic testing provides additional 
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information to the clinical practice, but it should be focused on the selected 
patients with CHH (Boehm et al. 2015).  
The reversal CHH variants manifest in a broad spectrum of pubertal progress 
and non-reproductive phenotypes (Raivio et al. 2007). Testicular growth during 
follow-up may reveal the partial gonadotropin secretion seen in the reversal 
phenotype, but, again, differentiating these subjects from patients with CDGP is 
challenging (Raivio et al. 2007). Recently, a study of Chan et al. suggested that 
administration of kisspeptin could aid in identifying patients with a reversal form of 
CHH (Chan et al. 2014). Patients with CHH, except reversal phenotypes, did not 
present an LH response to administered kisspeptin (Chan et al. 2014). 
Consequently, an experiment of treatment pause in hormone replacement therapy 
can reveal subjects with reversal phenotype later in life. 
1.4.3. Clinical features 
CHH is associated with a variable non-reproductive phenotype which includes, for 
example, the lack of smell (anosmia) or reduced capability to smell (hyposmia), 
cleft lip or/and palate, renal agenesis, mirror movements of hands (synkinesia), 
dental defects, micropenis, and cryptorchidism (Table 1) (Laitinen et al. 2011, 
Costa-Barbosa et al. 2013, Krams et al. 1999, Bailleul-Forestier et al. 2010, 
Molsted et al. 1997). The presence of these clinical cues can aid in the evaluation 
of an adolescent with suspected hypogonadism (Costa-Barbosa et al. 2013). 
Additionally, the non-reproductive features emphasize the need for a careful 
physical examination with special attention to the genitalia, teeth, and the 
neurological examination, when evaluating a patient with late puberty. Patients 
with CHH appear to grow relatively normally during childhood, but the impaired 
pubertal development results in the absence of growth spurt (Raboch & 
Reisenauer 1976, Kaushanski & Laron 1979) 
1.4.4. The differential diagnosis between CHH and constitutional delay of 
growth and puberty 
The early diagnosis of CHH remains as a dilemma (Boehm et al. 2015). 
Distinguishing prepubertal patients with CHH from those with CDGP, especially 
boys, is the most challenging process (Harrington & Palmert 2012). The only 
definite method to separate these two groups is to wait for the CDGP patients to 
show a complete and spontaneous progression of puberty. The difficult differential 
diagnosis between CDGP and CHH can result in an unnecessary delay in the 
diagnosis of CHH (Boehm et al. 2015). Several clinical and biochemical markers 
with varying success are used in this diagnostic process (reviewed in Harrington 
& Palmert 2012, Palmert & Dunkel 2012) (Table 2). These include GnRH and 
hCG stimulation tests, sex hormone levels, and the levels of Sertoli cell markers 
(Table 2). However, none of the tests show a complete diagnostic accuracy 
(Table 2) (Segal et al. 2009, Dunkel et al. 1985, Coutant et al. 2010, Adan et al. 
2010, Grinspon et al. 2010), and most of the studies have been retrospective 
(Segal et al. 2009, Coutant et al. 2010, Sequera et al. 2002). Additionally, the 
absence of clinical signs used in the differential diagnostics in these studies is 
striking. The effectiveness of clinical cues in predicting the progression of puberty, 
such as cryptorchidism, has not been studied before. Thus, clinicians who 
evaluate patients with DP would benefit from such clinical predictors of pubertal 
outcome.  
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Table 2. The suggested cutoff levels, sensitivities, and specificities of clinical and biochemical 
markers used to differentiate between congenital hypogonadotropic hypogonadism and 









Baseline LH, IU/L 0.3-0.7 85-100 88-90 (Grinspon et al. 2010, Binder et al. 2015) 
Baseline FSH, IU/L 0.9-1.2 88-100 55-88 (Segal et al. 2009, Grinspon et al. 2010) 
GnRH induced LH 
response, IU/L 2.8-5.8 90-100 84 (Segal et al. 2009) 
GnRH induced FSH 
response, IU/L 3.7-4.6 90 52-80 
(Grinspon et al. 2010, Sequera et 
al. 2002, Binder et al. 2015) 
Testosterone, nM 0.5 93 100 (Segal et al. 2009, Grinspon et al. 2010) 
Inhibin B, pg/mL 28-35 80-100 75-100 (Segal et al. 2009) 
hCG test, nM 3.6 92 92 (Coutant et al. 2010, Rohayem et al. 2015) 
AMH, pmol/L 110 80 100 (Coutant et al. 2010) 
Testicular volume 
(mL) 3 93 45 (Segal et al. 2009) 
Combinations     
Inhibin B and LH 
(pg/mL, IU/L) 35 and 0.5 100 100 (Coutant et al. 2010) 
Values lower than the cutoff levels increase the probability of CHH 
 
1.4.5. Treatment  
The treatment options for CHH depend on the aim of the treatment. Similarly to 
the treatment of CDGP, sex hormones are used in CHH to induce secondary 
sexual characteristics and height growth (reviewed in Boehm et al. 2015). In 
infants, cryptorchidism should be corrected during the first year of life as the 
untreated undescended testes are associated with impaired future fertility 
potential (Lee et al. 1996, van Brakel et al. 2013, van Brakel et al. 2014). Similarly, 
short term low-dose testosterone treatment in early infancy induces sufficient 
penile growth in patients with micropenis (Hatipoglu & Kurtoglu 2013, Landier, 
Chaussain & Job 1984). The adolescent boys are treated with testosterone and 
girls with estrogen to induce virilization and pubertal growth. The treatment 
reduces the risk for psychosocial disturbances caused by sexual infantilism 
(Dwyer et al. 2014). The dosage of sex steroids is gradually increased, mimicking 
the physiological rise in sex steroid levels that occurs during puberty. Also, the 
secondary sexual characteristics can be achieved by using pulsatile GnRH or 
hCG alone or in combination with recombinant FSH (Raivio, Wikstrom & Dunkel 
2007, Zacharin et al. 2012). These treatment modalities induce testicular growth, 
spermatogenesis, and are associated with improved HRQoL scores (Boehm et al. 
2015, Shiraishi, Oka & Matsuyama 2014). However, the previous patient series 
have included only a limited number of subjects, and the results need to be 
repeated in a large sample of CHH patients. After the induction of puberty, the 
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adequate sex hormone dosage is titrated by using the baseline levels of 
testosterone or estradiol. 
1.4.6. Long-term impact of sex steroid deficiency on bone-health and 
health-related quality of life 
Pubertal development is crucial for a normal acquisition of bone mineral content 
and bone density. Findings in menopausal women have shown a direct negative 
relationship between estrogen levels and bone density (Ahlborg et al. 2003). 
Similarly, hypogonadal men have a lower bone mineral density than those with 
normal testosterone levels (Canale et al. 2000). Patients with CHH and insufficient 
hormone replacement therapy have an increased risk for osteoporosis (Laitinen 
et al. 2012a, Finkelstein et al. 1989). Hormone replacement therapy restores bone 
health and emphasizes the life-long need of hormonal replacement therapy in 
patients with CHH (Laitinen et al. 2012a, Canale et al. 2000). 
Hypogonadism has adverse effects on general well-being and psychosocial 
long-term outcomes. HRQoL scores in men with CHH suggest that CHH is 
associated with an impaired quality of life (Aydogan et al. 2012, Shiraishi, Oka & 
Matsuyama 2014, Dwyer et al. 2014, Lasaite et al. 2013). These studies included 
mixed study populations and an unclear characterization of CHH (Aydogan et al. 
2012, Shiraishi, Oka & Matsuyama 2014, Lasaite et al. 2013). Aydogan et al. 
reported lower HRQoL scores in men with CHH, particularly in general health and 
emotional domains of HRQoL (Aydogan et al. 2012). These men had higher 
depression scores when evaluated with Beck Depression Inventory (BDI). After 
the beginning of testosterone therapy, both the HRQoL and BDI scores improved 
(Aydogan et al. 2012). The studies, however, did not evaluate the impact of the 
non-reproductive phenotype of CHH or the age of diagnosis on HRQoL. 
2. THE HORMONAL REGULATION OF GROWTH 
Human growth has been categorized into three different components (infancy, 
childhood, and puberty) by using the Karlberg’s growth model (Karlberg 1989). 
Each phase is controlled by a distinct hormonal and biological mechanisms: for 
example, sex steroids are the major regulators of growth during puberty (Karlberg 
1989). During the last decade, several studies in both developing and developed 
countries have reported an increase in mean height (Saari et al. 2011, Cole 2000, 
Roelants, Hauspie & Hoppenbrouwers 2009). This trend is probably due to the 
changes in environmental factors such as nutrition that regulate growth. Due to 
this secular trend observed also in Finland, national growth references should be 
updated from time to time (Saari et al. 2011, Sorva et al. 1990, Sorva, Tolppanen 
& Perheentupa 1990).  
2.1. Fetal life and infancy 
Fetal growth is dependent on materno-placental environment, and the main 
hormonal contributors to growth are insulin, IGF-1, and IGF-2 (Murray & Clayton 
2013). In rodents, the expression of Igf2 is widespread in fetal tissues during the 
last trimester, and deleting Igf1 or Igf2 results in fetal growth retardation (Fowden 
2003). Elevated transcription of IGF-2 results in overgrowth (Sparago et al. 2004), 
whereas a down-regulated IGF-2 expression is associated with perinatal growth 
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retardation (Gicquel et al. 2005). Altogether, linear growth in early gestation is 
more rapid in boys (Pedersen 1982). Growth velocity increases during the first two 
trimesters and peaks at mid-gestation (2.5 cm/week) (Underwood & Van Wyk 
1992). The role of androgens in this process is unclear. Infants with congenital 
adrenal hyperplasia (CAH), which is a condition of fetal androgen excess, have a 
higher birth length than healthy controls. Conversely, the newborns with complete 
androgen insensitivity syndrome (CAIS) show similar birth length to the general 
population (Balsamo et al. 2006, Miles et al. 2010). These findings suggest that 
androgens may contribute to fetal growth. 
Very little is known about the contribution of sex steroids on the growth during 
infancy as well. The transient postnatal activation of the HPG axis appears to 
interact with an early infancy growth. During minipuberty, serum testosterone 
levels, but not estradiol, correlates with penile growth and growth velocity (Boas 
et al. 2006, Kiviranta et al. 2016). Boys experienced a length velocity up to 4 cm/yr 
faster than the girls during minipuberty. The peak growth velocity occurs 
simultaneously with the average age of the peak gonadal activation (at 1 month 
of age) (Kiviranta et al. 2016). Interestingly, the levels of IGF-1 remain similar in 
boys and girls during the first six month of life, which suggests that the GH/IGF-1 
axis is not stimulated despite the elevated sex steroid levels (Kiviranta et al. 2016). 
These findings suggest that androgens modulate growth in early infancy, and the 
influence appears to be mediated directly on target tissues. 
During the first two years of life, infants experience catch-up or catch-down 
growth which suggests that early infancy growth compensates the growth during 
fetal life. In detail, birth size correlates poorly with parental size, whereas after the 
first two years the correlation improves significantly (Murray & Clayton 2013). The 
phenomenon has been explained with a central mechanism that detects and 
balances the difference between the expected and the actual size, or that it is a 
result of compensatory mechanisms of growth plate stem cells to growth delay 
(Murray & Clayton 2013). The growth during infancy is controlled by the combined 
effects of thyroid hormone, GH/IGF-1 axis, and nutrition. Diet induces IGF-1 
production in the liver (Socha et al. 2011, Ong et al. 2009, Low et al. 2001). 
Besides liver, IGFs are produced in the target tissues. Locally produced IGF-1 is 
a more potent growth contributor than the liver produced molecule, since in mice, 
removing the hepatic igf1 does not inflict a significant growth retardation (Liu, 
Yakar & LeRoith 2000). In humans, the phenotype of genetic IGF-1 deficiency 
includes deafness, intellectual disability, and pre- and postnatal growth retardation 
(Netchine et al. 2011). The most important target tissue of IGFs is the epiphyseal 
growth plate. In the growth plate, linear bone growth is achieved by the 
endochondral ossification. Chondrocytes not only express receptors for IGF-1, but 
also produce IGF-1 locally. In mice, the chondrocyte-derived IGF-1 and IGF-2 
contributes significantly to the linear bone growth (Smink et al. 2002). 
Consequently, the infancy growth is first a continuation of the rapid fetal growth. 
Length velocity is at the highest level during the first 3 months (20 cm/year), and 
then it gradually declines to 9 cm/yr at the average age of 3 yrs (Thiering et al. 
2012, Molinari, Gasser & Largo 2013). 
2.2. Childhood 
After infancy, the primary role of nutritional component in the regulation of growth 
is replaced by GH stimulation on IGF-1 synthesis in liver and in target tissues 
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(Murray & Clayton 2013, Chellakooty et al. 2006, Rosenfeld 2006, Baumann 
2001). At the same time, the importance of thyroid hormone in the growth 
regulation increases. Hypothyroidism results in the reduction of GH and IGF-1 
levels, and also an impaired chondrocyte proliferation and hypertrophy in the 
growth plate (Schmid et al. 2006, Kindblom et al. 2001, Stevens et al. 2000). The 
influence of sex steroids on childhood growth is unclear. Supraphysiological levels 
of androgens, if aromatized to estrogens, promote growth since children with 
excessive androgen production (i.e. CAH) have higher growth velocity and BMI 
values and a higher risk of childhood obesity than their peers (Volkl et al. 2006) 
(Merke et al. 2000). This suggests a programming contribution of androgens to 
the body composition during childhood. Furthermore, obese children show 
increased levels of dehydroepiandrosterone, a more advanced bone age 
throughout childhood, and an increased height standard deviation score (SDS) at 
the onset of puberty (Denzer et al. 2007, Johnson et al. 2012, Lass et al. 2011). 
This has been thought to result from an increased aromatase activity in the 
adipose tissue (Polari et al. 2015). In contrast, hypogonadism has been 
considered to contribute little to childhood growth. Importantly, male patients with 
androgen insensitivity syndrome have a tendency towards increased height 
growth during late-childhood and adolescence (Hellmann et al. 2012). Children 
with very rapid infant weight gain have higher levels of adrenal androgens during 
childhood (Ong et al. 2004). An excessive weight gain associates with an earlier 
pubertal development (Lee et al. 2016), albeit a certain amount of weight is critical 
for the normal onset of puberty (Frisch 1994). All in all, childhood growth is mainly 
GH dependent, which results in an average annual height velocity of 6 cm in mid-
childhood which then declines to 5 cm/yr before the onset of puberty (Kelly et al. 
2014). Further, the height velocity continues to decline steadily in a case of an 
absent pubertal growth spurt (Rikken & Wit 1992). 
2.3. Puberty 
During puberty, the constant childhood growth is gradually changed to the rapid 
pubertal growth. During the transition, childhood growth slows to its nadir right 
before the pubertal growth acceleration, which results in a period of very slow 
height velocity (i.e. peripubertal growth dip) (Rogol, Roemmich &  Clark 2002). 
Pubertal growth has been traditionally categorized into three phases: the time of 
growth acceleration (i.e. take-off velocity) right before the actual growth spurt, the 
time of most rapid growth (i.e. peak height velocity), and the phase of decreased 
growth velocity and the fusion of the epiphyseal cartilage (Tanner et al. 1976). The 
peak pubertal height velocity is reached at 1 to 2 yrs after the onset of puberty 
(Wehkalampi et al. 2011, Abbassi 1998), and girls reach it approximately 2 yrs 
before boys, which is likely due to the more rapid rise in estradiol levels reported 
in early pubertal girls (Marshall & Tanner 1970, Janfaza et al. 2006). During the 
growth spurt, the average height velocity is 8 cm/yr in girls, whereas boys exhibit 
even faster growth (9 cm/yr) (Abbassi 1998). Then the height velocity steadily 
decreases as the epiphyseal plates fuse. In both sexes, estrogen has a pivotal 
role in the induction of the growth spurt (Juul 2001, Morishima et al. 1995, Carani 
et al. 1997). Estrogen levels stimulate pituitary GH release and IGF-1 production 
in the liver and in target tissues (Venken et al. 2005, Mauras et al. 1987). More 
evidence supporting the role of estrogen in the stimulation of GH/IGF-I axis has 
accumulated from studies in boys treated with AIs. Adolescent boys treated with 
AI (anastrozole or letrozole) showed a decrease in IGF-1 concentrations during 
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follow-up (Mauras et al. 2000, Neely et al. 2014), whereas one study found no 
change in IGF-1 levels during anastrozole-treatment (Mauras et al. 2008). 
Treating CPP patients with a GnRH analog decreases not only the levels of 
gonadotropins and sex steroids but also the levels of IGF-1 and IGF-binding 
protein 3 (Muller et al. 2000, Juul et al. 1995). Additionally, estrogen induces 
growth plate senescence and maintains bone health by stimulating chondrocytes 
and osteoblast invasion in the epiphyseal plate (Shim 2015, Kusec et al. 1998, 
Yin et al. 2015). In boys, estradiol levels correlate positively with bone mineral 
density (BMD) (Doneray & Orbak 2010). The highest bone mineral content is 
achieved earlier in girls, whereas boys accumulate higher bone mass and more 
pronounced bone expansion (i.e. periosteal apposition) mainly due to longer 
period of bone acquisition (reviewed in Bonjour & Chevalley 2014). During 
puberty, testosterone induces protein synthesis and lipolysis, and increases 
muscle mass and BMD (Doneray & Orbak 2010, Mauras et al. 2003, Hero et al. 
2006). Thus, adolescent boys accumulate significantly more fat free mass in 
contrast to girls who gain more fat mass during the same period (Fintini et al. 2011, 
Garnett et al. 2004). Altogether, the absence of puberty results in low bone mineral 
content, osteoporosis, and the absence of pubertal growth spurt which are all 
observed in patients with CHH (Laitinen et al. 2012a, Van Dop et al. 1987). 
2.4. Adult height 
Adult height is regulated by genetic factors. Interestingly, a genome-wide 
association study found 423 loci, but could not focus single genes, that influenced 
on adult height (Wood et al. 2014). Evidence suggests that the majority of these 
genes do not participate in the GH/IGF-1 axis, but are associated with for example 
fibroblast growth factor signaling (Wood et al. 2014, Lui et al. 2012). After the 
growth spurt, the adolescents continue to grow until the epiphyseal plates fuse. 
Thus, the deficiency of sex steroids and the absence of puberty are likely to result 
in a longer period of growth and a taller adult height. In fact, this is best 
demonstrated in the patients with aromatase deficiency or with CHH as they 
typically exceed their genetic growth potential and their adult height is above the 
height of the general population (Morishima et al. 1995, Raboch & Reisenauer 
1976, Dickerman, Cohen & Laron 1992, Uriarte et al. 1992). Conversely, a 
premature closure of the epiphyseal plates reduces the adult height. In patients 
with CPP, a short childhood growth phase together with an early timing of the 
growth spurt and bone maturation result in a height loss and shorter adult height 
in contrast to the general population (Carel & Leger 2008, Bertelloni & Mul 2008).  
2.5. Evaluation of growth 
Adult height estimates are used by clinicians to predict the height reached after 
puberty. Genetic growth potential can be estimated with the mid-parental target 
height (MPH). In Finland, the MPH is calculated by using the formula: 0.886 x 
([father’s height + mother’s height] / 2 + 6.8 – 178.9066) / 6.6784 – 0.071 (Saari 
et al. 2011). However, MPH is only a rough estimate of the growth potential 
regardless of the individual variation in pubertal timing and bone maturation. 
Statural growth continues until the epiphyseal cartilages fuse. Thus, a more 
precise estimate of the individual growth potential at a certain calendar age is 
achieved by determining the current bone age from the wrist and hand x-ray. Bone 
age is visually estimated by using the radiographic atlases of skeletal maturation 
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(Tanner et al. 1983, Greulich & Pyle 1959). Subsequently, the individual timing of 
puberty (precocious, normal, and delayed) and the determined bone age are 
subjected to an adult height prediction model which produces a prediction of adult 
height (Bayley & Pinneau 1952). As the bone age estimate depends solely on the 
view of the assessor, it is susceptible to variation. Recently, the discovery of 
computerized assessment of bone age has made the evaluation of skeletal 
maturation easier and the adult height predictions more precise (Thodberg et al. 
2009). This automated bone age calculation is widely implemented to the clinical 
practice. 
Growth velocity may provide cues of chronic illnesses, albeit a number of 
conditions may manifest in impaired growth (Tuchman et al. 2008, Taylor et al. 
2012, Sankilampi et al. 2013). The evidence that support growth velocity to be 
used in the screening chronic diseases is inadequate. A recent review collected 
data from 69 articles which reported growth monitoring algorithms to detect 
chronic growth inhibiting disorders such as GH deficiency, Turner syndrome (TS), 
celiac disease, and cystic fibrosis (Scherdel et al. 2016). The meta-analysis found 
out that only the clinical decisions rules to detect patients with TS, coeliac disease 
and cystic fibrosis had sufficient specificities (Scherdel et al. 2016). In accordance, 
the evidence on the diagnostic performance of growth velocity to detect subjects 
with an abnormal pubertal development is scarce and limited to delayed puberty 
(Palmert & Dunkel 2012). It has been suggested that the annual growth velocity 
less than 3 cm could aid in identifying patients with delayed puberty caused by a 
chronic disease (Palmert & Dunkel 2012). Conversely, a steep growth curve 
together with advanced bone age in subjects with clinical signs of CPP supports 
the premature activation of the HPG axis (Fuqua 2013).  
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AIMS OF THE STUDY 
This study was conducted to evaluate the interactions between the HPG axis and 
growth from early infancy to adult height, and to describe the etiology and outcome 
of delayed puberty. The specific aims were: 
1. to investigate if circulating MKRN3 levels could serve as a read-out of the 
diminishing central restrain on the HPG axis (I) 
 
2. to characterize the diagnoses that underlie delayed puberty and predictors 
of its clinical course (II) 
 
3. to depict the growth patterns of patients with congenital hypogonadotropic 
hypogonadism from birth to adult height (III-IV) 
 
4. to evaluate the health-related quality of life in men with CHH (V)
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PATIENTS AND METHODS 
3. STUDY SUBJECTS 
3.1. Boys with idiopathic short stature (ISS) (I) 
The boys with idiopathic short stature (ISS) participated in a randomized placebo-
controlled double-blind trial, in which 16 boys were treated with letrozole (Lz) (2.5 
mg/d) and 14 received placebo (Pl) for two years (Hero, Norjavaara & Dunkel 2005). 
At the beginning of the study, the boys had a mean age of 11 years (range: 9.1 - 14.2 
yrs). The chronic diseases that can cause short stature were excluded by using 
growth curve analysis, serum IGF-I level, and in subject with a suspicion of GH 
deficiency, a GH stimulation test. The boys were investigated every 6 months for 2 
years, and the follow-up protocol included a final visit at 36 months after the beginning 
of the study. At the visits, testis size was calculated by using the formula: length x 
width2 x 0.52, and pubertal stage was recorded (Marshall & Tanner 1970, Behre, 
Nashan & Nieschlag 1989). At the beginning of the study, 28 boys were prepubertal 
(G1), one boy was at G2 (testicular volume above 3 mL), and one at G3 (Hero, 
Norjavaara & Dunkel 2005). During the two years of the treatment, eight boys who 
were treated with Lz and eight who received Pl showed signs of puberty progression, 
whereas at 36 the months visit seven out of 10 with Lz and six out of 11 boys with Pl 
were pubertal (Hero, Norjavaara &  Dunkel 2005). Additionally, six boys fulfilled the 
criteria of delayed puberty (i.e. G1 at the age of 14 yrs or older). Letrozole which is a 
potent third-generation AI, effectively inhibited the estrogen biosynthesis as indicated 
by low serum estradiol levels in the treated boys despite stimulated testosterone 
secretion (Hero, Norjavaara & Dunkel 2005, Wit, Hero & Nunez 2011).  
3.1.1. Collection and analyses of the serum samples 
The serum samples of boys with ISS were used (Hero, Norjavaara & Dunkel 
2005). The obtained serum was stored at -20 or -80 C until the hormonal analyses 
were performed. Gonadotropin levels were measured with an ultrasensitive 
immunofluorometric assays (Wallac, Turku, Finland), inhibin B levels with 
immunoenzymometric assay (Serotec, Oxford, UK), and testosterone levels with 
a modified RIA (Hero, Norjavaara & Dunkel 2005). Serum MKRN3 levels were 
quantified by using the commercially available Human MKRN3 enzyme-linked 
immunosorbent assay (ELISA) kit (MyBioSource, San Diego, CA, USA) with the 
sensitivity of 7.8 pg/mL, the within assay CV of 6%, and the between assay CV of 
9.2%. Before the analyses, the samples were diluted (1:8) according to the 
instructions in order to lower the MKRN3 levels to the measuring range of the kit. 
The final MKRN3 level was achieved by multiplying the measured level with 8.  
3.2. Patients with DP (II) 
The patients (408 boys and 181 girls) had been investigated for DP at the Pediatric 
Endocrine Outpatient Clinic of Helsinki University Hospital between 2004 and 2014 
and were identified with an ICD-10 code-based inquiry to the electronic patient 
information system (Figure 4). The used ICD-10 codes were E28, E28.3, E28.8, 
E28.9, E29, E29.0, E29.1, E29.8, E29.9, E30.00, E30.09, E30.8, and E30.9.  
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Of the 589 patients, 244 (174 boys and 70 girls) fulfilled the criteria of DP 
(Figure 4). The medical records included information about Tanner stages in 244 
(100%), bone age in 227 (93%), baseline LH 216 (88%) and FSH levels in 216 
(88%) and 218 (89%), sex steroid levels in 217 (89%). Of the second line 
investigations of DP, a GnRH test was performed in 104 (43%) and inhibin B levels 
in 126 (72%) boys. A growth hormone (GH) stimulation test was performed in 15 
patients (8 boys and 7 girls), and two of them (panhypopituitarism and juvenile 
rheumatoid arthritis) had a result which suggested a GH deficiency. A ruler-
measured testicular volume was available in 120 (69%) subjects. Height 
measurements, which were taken at least every six months, were available in 230 
(94%) boys, which enabled the calculation of the annual height velocity. The 
timing of puberty in the first degree relatives of the patients was recorded in all 
patients, and puberty was considered late if a sister or the mother had reached 
menarche after 14 yrs, or a brother or the father had experienced late puberty or 
delayed growth spurt. 
 
Figure 4. A flowchart describing the patient recruitment for study II. a 
Patients were identified by an ICD-10 code-based inquiry (E28, E28.3, 
E28.8, E28.9, E29, E29.0, E29.1, E29.8, E29.9, E30.00, E30.09, E30.8, 
and E30.9) (Modified from II). 
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3.2.1. Classification of different DP types 
The diagnoses of DP were classified into the four main diagnostic categories: 
FHH, PHH, Hyper H, and CDGP (Sedlmeyer & Palmert 2002). The diagnosis of 
CDGP was confirmed when the clinical, the hormonal, and the radiologic data 
ruled out pathological causes of DP. Further, in most of the cases with CDGP 
(86%), the progression of puberty was confirmed in the hospital outpatient clinic, 
whereas the remaining cases were followed up in the school health care. 
However, none of the patients were referred back to the tertiary center for an 
evaluation of pubertal progress.  
The PHH group consisted of patients with a confirmed pathology in the CNS, 
or an organic cause for the hypogonadism, and/or low LH and FSH and sex steroid 
levels, and without any spontaneous progression of puberty until the age of 18 
yrs. Of the 19 patients with PHH, 16 (11 boys and five girls) had CHH as the cause 
of the permanent hypogonadism. In the remaining three patients, PHH was 
caused by Prader-Willi syndrome, panhypopituitarism, and craniopharyngioma. 
The patients with FHH had an identified disease that likely delayed pubertal 
onset, but the patients showed a spontaneous progression of puberty during the 
follow-up. Interestingly, a spontaneous progression of puberty was confirmed in 
14 girls and 15 boys (97%) with FHH within the next three yrs after the initial 
evaluation of puberty. The patients with FHH had no hormonal or clinical signs 
which suggested the presence of permanent hypogonadism. Additionally, the 
FHH group included patients with anorexia nervosa and those with severe 
underweight. These patients had age- and sex-matched BMI (ISO-BMI) values 
below 16 kg/m2 prior to the initial evaluation (Saari et al. 2011). Finally, the 
diagnosis of Hyper H was confirmed with gonadal failure and high baseline LH 
and FSH levels. Remarkably, a history of prior cryptorchidism was reported in the 
three boys with CDGP (unilateral) and in four boys with CHH (two unilateral and 
two bilateral), whereas none of the patients had a history of micropenis. The 
methods used to determine the levels of gonadotropins, sex steroids and inhibin 
B between 2004 and 2014 are described in Table 3 (Table 3). 
Table 3. The methods used to determine gonadotropins, sex steroids and inhibin B levels in 
studies II-V.  
Hormone(s) Method Period Detection limit Manufacturer Study 





immunoassay 2011 -  0.1 IU/L 
Roche Diagnostics, 
USA II 
Estradiol Radioimmunoassay 2004 - 2009 30 pmol/L DiaSorin S.p.A,Vercelli, Italy II 
 
Radioimmunoassay 2009 - 2014 30 pmol/L AutoDELFIA, Perkin-Elmer, Turku, Finland II, IV 
 
Immunoluminometric assay 
or mass spectrometry 2014 -  10 pmol/L 
Siemens Healthcare 
Diagnostics, Germany II 






Mass spectrometry 2005 -  0.05 nmol/L AB Sciex, Foster City, California, USA II, III, V 
Inhibin B ELISA  2004 - 2010 7 pg/mL 
Oxford Brooks Innovation 
and Diagnostics Systems 
Laboratories, UK 
II 
  ELISA  2010 -  2.6 pg/mL Beckman Coulter, Inc. USA II 
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3.3. Patients with CHH (III-V) 
The third study cohort included 36 patients (30 men and 6 females) with CHH who 
participated in the nationwide study of KS in Finland (Laitinen et al. 2011). In 
addition to the Finnish boys with CHH, the growth data of nine Danish patients 
were included (Tommiska et al. 2014). The diagnosis of CHH was based on i) 
absent or incomplete puberty at the age of 18 years and ii) low sex steroid levels 
accompanied by normal or subnormal gonadotropin levels and iii) otherwise 
normal anterior pituitary function and iv) no organic cause for their condition. 
Seven boys (six Finns and one Dane) did not meet the criteria since they were 
less than 16 yrs old at the time of diagnosis. Their diagnosis, however, was 
confirmed since the Finns had a history of prior cryptorchidism and/or micropenis, 
and no testicular growth during the clinical follow-up, whereas the Dane had a 
micropenis and very low minipubertal LH (< 0.05 IU/L) and testosterone (< 0.23 
nmol/L) levels. The molecular genetic diagnosis of CHH was confirmed in 22 
patients (Laitinen et al. 2011, Laitinen et al. 2012b, Tommiska et al. 2014). The 
girls all had a mutation in FGFR1 (n=6), whereas in boys with CHH, the gene 
mutations were categorized into three groups: the boys with mutations in ANOS1 
(n=7), FGFR1 (n=5), and into those with mutations in gonadotropin-releasing 
hormone receptor (GNRHR), chromodomain helicase DNA-binding protein 7 
(CHD7), or prokineticin 2 (PROK2) (n=4). Clinical signs of profound GnRH 
deficiency (history of micropenis or/and cryptorchidism) were reported in 23 (53%) 
(14 Finns and 9 Danes) subjects, whereas one girl had a cleft lip and none had 
bony anomalies.  Hormonal markers were determined in the laboratory of Helsinki 
University Central Hospital (HUCH). The used methods are described in detail in 
Table 3 (Table 3). 
3.3.1. Acquisition of growth data 
The growth data of six CHH girls with an FGFR1 mutation, and 36 boys with CHH 
(27 from Finland and 9 from Denmark) were reviewed retrospectively (Laitinen et 
al. 2011, Laitinen et al. 2012b, Tommiska et al. 2014). Height/length and weight 
were measured by trained nurses, and bone age was determined by the physician 
according to the Greulich and Pyle atlas. National reference data were used to 
calculate the height/length SDSs. We were especially interested in the linear 
growth during minipuberty. Thus, growth charts were carefully searched to obtain 
the length measurements at birth, and three and six months of age. When an 
exact measurement was not present at three or six months of age, we selected 
the nearest available measurement (at 3 months, range: 2-4 months, and at 6 
months, range: 5-7 months). Fifteen (42%) of the boys with CHH had 
representative length measurements (i.e. birth length and a length measurement 
at three or six months of age) during minipuberty, which allowed us to calculate 
the decline in length SDS from birth to three and six months of age. Subsequently, 
the length SDSs were compared with MPH SDSs, available in 11 (73%) boys with 
representative length measurements during minipuberty. Adult heights were 
available in 31 boys (23 Finns and 8 Danes) and in three girls. The MPH SDS 
(n=22) was calculated in Danes with the mean height SDS of mother and father, 
and in Finnish boys and girls by using the equations: 0.886 x ([father’s height + 
mother’s height] / 2 + 6.8 – 178.9066) / 6.6784 – 0.071, and 0.0611 x (father’s 
height + 0.0703 x mother’s height - 22.37), respectively (Saari et al. 2011). 
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In the boys with CHH, the mean age of pubertal induction was 16.1 yrs (range: 
12–21), whereas the corresponding age in girls was 15.7 yrs (range: 14.8–16.8). 
In 14 boys, the data permitted us to calculate the dosage of testosterone used 
during the first year of pubertal induction (mg/kg/yr). 
Before the age of 2 yrs, weight gain was characterized by using the weight-for-
length which is the percentage deviation of weight from the median weight for 
length and sex (%DW) (Sorva, Tolppanen & Perheentupa 1990). Thereafter, ISO-
BMI or BMI was used (Saari et al. 2011). The ISO-BMI values were categorized 
into severe underweight (ISO-BMI less than 16 kg/m2), underweight (16-17 
kg/m2), normal weight (17-25 kg/m2), overweight (25-30 kg/m2), and obesity (more 
than 30 kg/m2) (Saari et al. 2011).  
3.3.2. Health-related quality of life 
Health-related quality of life was evaluated in 30 men with CHH by using the 15D 
instrument (Sintonen 2001). At the evaluation visit, the mean age of the patients 
was 38.1 yrs (range: 16–61), and four patients had a reversal phenotype of CHH. 
The 15D is a descriptive questionnaire which includes questions about the 15 
different dimensions of health (mobility, vision, hearing, breathing, sleeping, 
eating, speech, excretion, usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality, and sexual activity). The answer to each 
question is classified into 5 levels (the best level=1; the worst level=5), and the 
alternative that best describes the current state is chosen. Thus, the questionnaire 
produces a single index score (15D score, scale from 0-1, 1=full health, 0=being 
dead) which represents the overall HRQoL, and a similar score for each 
dimension. Subsequently, population-based preference weights are implemented 
to the 15D scores which result in final comparable HRQoL scores (range 0–1). In 
this study, we compared the mean 15D score and the mean dimension values in 
patients with CHH to those of a general male population (n=1227). A clinically 
relevant difference in the 15D score is 0.03 (Alanne et al. 2015). 
4. STATISTICS 
Statistical analyses were conducted with SPSS statistical software, release 22.0 
(SPSS, Chicago, IL, USA). The data is presented with mean (SD) unless 
otherwise mentioned. The analyses between two groups were carried out with the 
t-test (I-II, V) or the Mann-Whitney U-test (I-II), whereas when comparing the 
height SDS to general population, one-sample t-test was used. Longitudinal 
length/height and weight measurements were analysed with the paired samples 
t-test. Correlations were determined with Spearman’s rank correlation (rs) (I-III, V). 
The correlations were two-sided, except for the correlation between the age of 
diagnosis and HRQoL (V). However, this was accepted since delayed diagnosis 
has been shown to associate with long-term psychological consequences (Dwyer 
et al. 2014). 
Categorical variables were analysed with the Fisher’s exact test. Odds ratios 
(OR) with 95% confidence intervals (CI) were calculated (II). The diagnostic 
accuracy of the clinical and hormonal markers of puberty were modelled with the 
receiver operating characteristic (ROC) curves with area under the ROC curve 
(AUC) and 95% CI. The ROC curves were interpreted and cutoff values which 
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maximized the sensitivity and the specificity were selected. For the risk prediction 
model of CHH in study II, the quality control (QC) measures of inhibin B were 
obtained between 2004 and 2014, and fitted in to a linear model that predicted the 
dispersion for each mean. Based on mean ± 2 standard error of the QC 
measurements, three inhibin B categories were created (10-49, 49-111, and 111-
212 ng/L). Subsequently, inhibin B levels of the patients were divided into the three 
categories. Finally, the combination of inhibin B category and testis size was 
subjected to a logistic regression model which predicted the disease risk. 
The longitudinal measurements of MKRN3, gonadotropins, testosterone, and 
inhibin B were investigated by implementing the method of summary measures 
(Matthews et al. 1990). Thus, a regression line was fitted to each patient’s 
measurements, with age as an independent variable and circulating MKRN3, 
testosterone, LH, FSH, or inhibin B levels as dependent variables. The obtained 
regression coefficients were analyzed as raw data with the t-test. The statistically 
significant level was set to P value less than 0.05. 
5. ETHICS 
The study protocol was approved by the Ethics Committee of the HUCH and 
Danish regional ethical committee, and the national agency of medicines (FIMEA) 
(I, III-V). A written informed consent was obtained from all subjects and their 
guardians. The study on the etiology of delayed puberty contained only data from 
the medical records without any contact to the patients. Thus, according to the 




1. Serum MKRN3 levels in boys before the clinical onset of 
puberty 
During the three year follow-up, circulating MKRN3 declined significantly (-669 ± 
713 pg/mL/yr, P < 0.001) (Figure 5). The overall decrease was similar between the 
Lz-treated boys (n=16) and those who received Pl (n=14) (-657 ± 750 vs -683 ± 690 
pg/mL/yr, P = NS). Subsequently, we investigated how MKRN3 levels changed 
during the progression of puberty, and analyzed the longitudinal changes in MKRN3 
levels in 13 boys with available measurements before and after the clinical onset of 
puberty (defined as genital stage 2). In these boys, the decline in MKRN3 level was 
more profound before G2 (2931 ± 2750 pg/mL/yr), than after the onset of puberty 
(560 ± 1510 pg/mL/yr, P < 0.05). Interestingly, before pubertal onset, the boys who 
were treated with Lz had a slower decline in MKRN3 levels (-782 ± 3190 pg/mL/yr) 
than those who received Pl (-2030 ± 1821 pg/mL/yr, P < 0.05). 
 
Figure 5. Panel A, the mean MKRN3 levels in boys with idiopathic short stature 
during the follow-up. Panel B, the mean MKRN3 levels adjusted for the clinical 
onset of puberty (genital stage 2, G2). Lines represent mean (blue) ±1 standard 
deviation (dashed line). 
 
Since MKRN3 is suggested to be a key inhibitor of GnRH neurons, we 
examined if circulating MKRN3 levels would associate with the clinical and the 
biochemical markers of puberty. Indeed, the decline in MKRN3 levels correlated 
negatively with testis sizes (rs= -0.3, P < 0.001), and the decline appeared to be 
faster at small testis sizes (Figure 6). Additionally, we examined the relationship 
between testicular growth and MKRN3 by determining the testicular volume for 
each patient at the time of the highest and the lowest measured MKRN3 level. At 
the highest MKRN3 level, the mean testicular volume was small (2.0 ± 2.9 mL), 
whereas larger testes sizes were observed at the lowest MKRN3 level (5.8 ± 4.5 
mL, P < 0.001). After excluding the two boys who showed an increasing 
longitudinal change in MKRN3 levels during the study period, we found that the 
rate of decline in MKRN3 levels (n=26) correlated negatively with the 
corresponding change in testosterone (rs= -0.6, P < 0.01), LH (rs= -0.5, P < 0.01, 
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n=26), and inhibin B levels (rs= -0.44, P < 0.05). The reciprocal association 
between serum MKRN3 levels and the levels of inhibin B in four individuals are 
described in Figure 8 (Figure 7). 
 
Figure 6. The association between testis size and serum 
MKRN3 levels (160 measurements) in 30 boys with idiopathic 
short stature (ISS) followed for 3 yrs (rs= -0.3, P < 0.001). The 
line represents the relationship between testis size and 
MKRN3 in 14 boys with ISS who received placebo (rs= -0.4, P 
< 0.001) (Modified from I). 
 
 
Figure 7. The reciprocal changes in circulating MKRN3 and inhibin B levels 
in four boys with ISS before and after the onset of puberty. 
 
Prepubertal boys treated with Lz and those with Pl had similar levels of 
testosterone, gonadotropin and inhibin B levels, testis sizes, and no difference in 
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the age of puberty onset (Hero, Norjavaara & Dunkel 2005). The six boys who 
were diagnosed with DP, however, experienced a significantly lower decline in 
MKRN3 levels than those with normal pubertal timing (-81± 612 vs -812 ± 671 
pg/mL/yr, P < 0.05), albeit we found no association between circulating MKRN3 
and parameters of pubertal timing: age at G2, time from the initial evaluation to 
G2, or bone age at G2 (rs= 0.05 – 0.3, P = NS). 
2. The underlying causes of DP 
We found 30 different diagnoses that underlie DP (Table 4). In both sexes, the 
most common cause was CDGP, and it was more frequent in the boys than in the 
girls (82% vs 56%, P < 0.001). Additionally, 63% of the boys and 69% of the girls 
with CDGP had a positive family history of DP (P = NS). The absolute number of 
girls with familial CDGP (n=27) was lower than the number of boys (n=90). In 
consequence of the lower number of girls with CDGP, the relative frequency of 
pathological conditions that underlie DP (i.e. FHH, PHH or Hyper H) was higher 
in girls (44% vs 18%, P < 0.05). The second most frequent cause of DP in both 
sexes was FHH. Further, a difference between the sexes was apparent in the FHH 
and Hyper H categories, since they both affected the girls more frequently than 
the boys (P < 0.001).  
Table 4. The number of different diagnoses that underlie delayed puberty at the 
pediatric outpatient clinic of Helsinki University Central Hospital between 2004 and 
2014 (n=244) (Modified from II). 
Diagnoses Male Female 
CDGP 142 (82%) 39 (56%) 
PHH 13 (7%) 6 (9%) 
Congenital hypogonadotropic hypogonadism 11 5 
Hypopituitarism 1  
Craniopharyngioma  1 
Prader-Willi syndrome 1  
FHH 16 (9%) 14 (20%) 
Severe underweight 4 3 
Anorexia 1 2 
Severe developmental delay 1 2 
Crohn´s disease 2  
Clinical CHARGE syndrome without CHD7 mutation 1 1 
VATER assosiation 1  
Cornelia de Lange syndrome  1 
Cartillage-hair hypoplasia  1 
Celiac disease  1 
Intense excercise  1 
Jacobsen syndrome and hypothyroidism  1 
Hydrocephalus 1  
Pulmonary fibrosis 1  
Juvenile idiopathic arthritis 1  
Systemic lupus erythematosus  1 
Radiation therapy for malignancy 1  
CNS disorders (Small Rathke´s cleft cyst or empty cella) 2  
Hyper H 3 (2%) 11 (15%) 
Anorchia 1  
Idiopathic testicular failure 1  
Idiopathic ovarian failure  6 
Chemotherapy for malignancy (Askin tumor)  1 
Turner syndrome  3 
FSH receptor gene mutation  1 
SRY-positive XX male 1   
CDGP, constitutional delay of growth and puberty; PHH, permanent hypogonadotropic hypogonadism; 
FHH, functional hypogonadotropic hypogonadism; Hyper H, hypergonadotropic hypogonadism; CHD7, 
chromodomain helicase binding protein 7. 
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Subsequently, we compared the distribution of the four diagnostic categories 
in our series to the frequencies reported in the most comprehensive study 
published so far (Sedlmeyer & Palmert 2002). In our series, the frequency of 
CDGP was significantly higher (in girls 56% and in boys 82%) than reported before 
(32% and 64%, P < 0.001, respectively) (Figure 8) (Sedlmeyer & Palmert 2002). 
By contrast, the frequency of FHH (9%) and Hyper H (2%) in boys, and PHH (15%) 
in girls, was significantly lower than proportion in the previous series (20%, 7%, 
and 25%, P < 0.05, respectively) (Figure 8).  
 
Figure 8. The distributions of the four main diagnostic groups that underlie late 
puberty in the two largest tertiary center patient series (Study II and Sedlmeyer & 
Palmert 2002). CDGP, constitutional delayed of growth and puberty; PHH, 
permanent hypogonadotropic hypogonadism; FHH, functional hypogonadotropic 
hypogonadism; Hyper H, hypergonadotropic hypogonadism. 
 
3. The differential diagnosis of DP 
A history of prior cryptorchidism was more frequent in those with PHH (30%) than 
in those with CDGP (2%) (P < 0.05). Similarly, patients with CHH (a subgroup of 
PHH) had undescended testes (36%) more commonly than those with CDGP (2%, 
P < 0.05). Thus, OR for a boy with DP and a history of cryptorchidism to have 
CHH was 26.5 (95% CI; 4.9-142, P < 0.001). By contrast, in late maturing boys 
without a history of cryptorchidism the risk of CHH was low (OR 0.04, 95% CI; 
0.01-0.2, P < 0.001), and the probability of CHH decreased even more if the boy 
had also a positive family history of DP (OR 0.01, 95% CI; 0.001-0.1, P < 0.01). 
Testicular volume, measured with a ruler, inhibin B and GnRH-induced LH 
levels were the most effective markers to discriminate between the prepubertal 
(genital stage 1 or testis size < 3mL) boys with CHH (n=10) and those with CDGP 
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(n=76), whereas equally effective markers could not be found in girls. Additionally, 
when testis size was combined with inhibin B or GnRH-induced LH levels, the 
diagnostic efficacy was improved even more. The performance of clinical and 
biochemical predictors of DP, and their combinations, are described in Table 5 
(Table 5) and Table 6 (Table 6).  
 
Table 5. The clinical and biochemical markers to discriminate between prepubertal boys with 
congenital hypogonadotropic hypogonadism (n=10) and those with constitutional delay of 
growth and puberty (n=76). 
Predictor AUC (95% CI) Cutoff level Sensitivity (%) Specificity (%) 
Baseline LH, IU/L 0.86 (0.73-0.98) 0.5 100 68 
Baseline FSH, IU/L 0.89 (0.75-1.00) 1.2 86 88 
GnRH-induced LH, IU/L 0.92 (0.83-1.00) 4.3 100 75 
GnRH-induced FSH, IU/L 0.81 (0.6-1.00) 3.3 86 72 
Testosterone, nM 0.74 (0.59-0.88) 0.6 91 42 
Inhibin B, ng/L 0.88 (0.74-1.00) 60 90 83 
Testicular volume, mL 0.95 (0.87-1.00) 1.1 100 91 
Combinations     
Inhibin B and testicular 
volume 0.95 (0.87-1.00) 
   
GnRH-induced LH and 
testicular volume 0.98 (0.94-1.00)       
AUC, area under the curve; CI, confidence interval. Values lower level than the cutoff levels increase 
the probability of CHH. 
 
Table 6. The biochemical markers used to discriminate between prepubertal girls with 
congenital hypogonadotropic hypogonadism (n=5) and those with constitutional delay of 
growth and puberty (n=36).  
Predictor AUC (95% CI) Cutoff level Sensitivity (%) Specificity (%) 
Baseline LH, IU/L 0.53 (0.26-0.80) 0.3 80 40 
Baseline FSH, IU/L 0.82 (0.53-1.00) 1.2  80  95 
GnRH-induced LH, IU/L 0.78 (0.43-1.00) 1.7 80 95 
GnRH-induced FSH, IU/L 0.80 (0.45-1.00) 4.2 80 95 
Estradiol, nM 0.58 (0.34-0.80) 0.05 80 45 
AUC, area under the curve; CI, confidence interval. * Estradiol level 0.05 nmol/l is the detection limit of 
the assay. Values lower level than the cutoff levels increase the probability of CHH. 
 
While in a search for new methods that would aid in the challenging differential 
diagnosis between CHH and CDGP, we developed a clinical risk prediction model 
for CHH which takes advantage of the performance of different inhibin B analyte 
concentrations and testicular volume.  In brief, testicular volumes and inhibin B 
levels were combined in a logistic regression analysis which estimated the 
probability of CHH in a given inhibin B level and testicular volume (Table 7). The 
RESULTS 
48 
risk for CHH was the highest at small testicular volumes (< 1mL) and low inhibin 
B levels (< 50 ng/L). 
 
Table 7. The mean probability of CHH according to 
testicular volume and inhibin B level. The inhibin B 
categories were calculated from the quality control 
measurements of inhibin B (mean ± 2 standard deviation) 
between 2004 and 2014. 
Inhibin B (ng/L) 
Testis size 
<1.0 mL 1.1-2 mL 
10-49 90 (50-100)* 20 (0-80) 
49-111 60 (10-100) 10 (0-40) 
111-212 20 (0-90) 0 (0-10) 
*Probability is presented with mean percentage (range)  
 
Subsequently, the performance of the growth velocity to differentiate between 
the four diagnostic categories of DP was evaluated. We found that boys with FHH 
(n=18) had a lower mean height velocity than those with CDGP or CHH (n=142) 
(3.2 ± 1.2 vs 4.1 ± 1.7 cm/yr, P < 0.05, respectively). Since it has been suggested 
that height velocity below 3 cm/yr could identify patients with FHH from those with 
CDGP or CHH (Palmert & Dunkel 2012), we categorized the boys and the girls 
into those whose height velocity was above 3 cm/yr and into those who grew 
slowly (< 3 cm/yr). In girls, the frequencies of the four diagnostic categories (i.e. 
CDGP, PHH, FHH, and Hyper H) did not differ between the two growth categories. 
Conversely, in boys, the number of cases with FHH was significantly higher in 
boys who grew slowly than in those with height velocity more than 3 cm/yr (19% 
vs 4%, P < 0.05). However, the ROC analysis of growth velocity revealed that the 
previously suggested growth velocity cutoff level of 3 cm/yr discriminated the boys 
with FHH from those with CDGP or CHH only with a sensitivity of 50% and a 
specificity of 80% (Palmert and Dunkel, 2012). Next we evaluated the efficacy of 
annual growth velocity to identify the patients with an abnormal brain MRI scan. 
Brain MRI was performed in 39 patients (24 boys and 15 girls), and it was 
considered abnormal in 6 cases: one girl with a craniopharyngioma, two boys with 
a Rathke’s cleft cyst, two with a hypothalamic hamartoma, and one with empty 
cella. The girl with the craniopharyngioma grew very slowly (2 cm/yr), while the 
mean growth velocity of the boys with an abnormal MRI scan was similar to those 
with a normal MRI scan (n=18) (3.5±0.9 vs 4.2±2.4 cm/yr, P = NS). 
4. The growth of patients with CHH from birth to adult height 
The boys with CHH (III) showed a significant decrease in the mean length SDS 
from birth (0.2 ± 1.6 SDS) to 3 months (-0.9 ± 1.2 SDS, P < 0.01) and to 6 months 
of age (-0.7 ± 1.3 SDS, P < 0.05). The mean length SDSs at 3 and 6 months of 
age were lower than their MPH SDSs (-0.02 ± 0.9 SDS, P < 0.05) and, at 3 months 
of age, lower than the length SDSs of the general population (-0.9 ± 1.2 SDS, P < 
0.05). The presence of minipubertal growth deflection was further evaluated by 
excluding four patients with birth length above the normal range (±2SD). Despite 
excluding the four patients, the length deflected from birth (-0.3 ± 1.3) to 3 months 
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of age (-1.0 ± 1.3, P < 0.01). The boys with CHH experienced a reduction in 
weight-for-length from birth (2 ± 10%) to 6 months of age (-4 ± 10%, P < 0.05). 
Subsequently, we evaluated separately the growth rate of patients with signs 
of a severe GnRH deficiency (i.e. a history of cryptorchidism and/or micropenis). 
These males (n=8) experienced a profound length SDS deflection from birth (0.8 
± 1.8 SDS) to 3 (-1.0 ± 1.4 SDS, P < 0.01) and to 6 months of age (-0.5 ± 1.2 SDS, 
P < 0.05) (Figure 9).  
 
Figure 9. The length standard deviation scores (SDS) of CHH 
patients with (dark grey) and without (light grey) a history of 
micropenis and/or cryptorchidism.* P < 0.05, ** P < 0.01. 
 
The length SDS of CHH patients with verified gene mutations decreased 
significantly from birth (0.1 ± 1.1 SDS) to 3 months of age (-1.0 ± 0.9 SDS, P < 
0.01). At 3 months of age, the boys had lower height SDS than the general 
population (-1.0 ± 0.9 SDS, P < 0.05), and the boys with ANOS1 (n=7) had a lower 
birth length than those with FGFR1 (n=4) (-0.7 ± 0.8 vs 0.8 ± 0.8 SDS, P < 0.05, 
respectively). 
The boys with CHH grew relatively normally during childhood, but at the 
average age of 7 years (n=31), their mean height SDS (-0.8 ± 1.3 SDS) was lower 
than their mean MPH SDS (0.07 ± 0.7 SDS, P < 0.05) and the height SDSs of the 
general population (P < 0.01). During adolescence, the height SDS reached its 
nadir (-1.8 ± 1.4 SDS) at a mean age of 15.8 yrs, and thereafter the boys 
experienced an increased growth velocity as a result of the induction of puberty. 
The dosage of testosterone used during the first year of puberty induction (mean 
dosage 30, range 5 – 114 mg/kg/yr) in 14 patients correlated negatively with the 
adult height (rs= -0.7, P < 0.05) (Figure 10A), but no association was found 
between the age at puberty induction and the adult height (rs= 0.1, P = NS). 
Further, the boys with CHH had a mean adult height of -0.4 ± 1.3 SDS which was 
similar to the adult heights of the general population, their MPH SDSs, and did not 
differ between gene mutations (P = NS). We found a decreasing trend in the age 




Figure 10. Panel A, The correlation between adult height and the cumulative 
dosage of testosterone during the first year of puberty induction. Panel B, the 
trend in the age of puberty induction between 1970 and 2012 (III). 
 
The girls with CHH (IV) and FGFR1 mutations experience an unremarkable 
growth during early infancy, since length SDS did not deviate with the exception 
of one girl whose height SDS decreased from birth (-0.8 SDS) to 6 months of age 
(-1.5 SDS). Thus, the transient height SDS deflection seen in boys with CHH boys 
was not evident in the growth curves of the girls with CHH. Similar to the boys with 
CHH, the height SDSs of the girls decreased during childhood. The deflection in 
the height curve began at the age of 4 to 7 yrs, and the mean height SDS of the 
girls reached its nadir (-1.8 SDS) at the average age of 14.5 yrs, which occurred, 
as in boys with CHH, right before the induction of puberty. 
The late sexual maturation was also apparent in the bone maturation of the 
girls, since they had a mean delay of 2.4 yrs (range: -3.2–(-1.9) yrs) in the bone 
age. In the three girls, with available adult heights, the adult height SDSs minus 
MPH SDSs ranged from -0.2 to 1.2 SDS. All subjects had normal weight 
development, as their BMI trajectories were within the normal limits.  
5. Health-related quality of life in males with CHH 
The male patients with CHH had a lower mean 15D score than the age-matched 
general male population (0.918 ± 0.074 vs 0.948 ± 0.067, P < 0.05). In particular, 
the dimensions most affected were depression and distress (Figure 11). Although 
a continuous sex steroid treatment is essential to prevent the long-term 
consequences of CHH, we found no association between the testosterone levels, 
or the total duration of hormone replacement therapy pauses and the 15D scores 
(P = NS). Subjects with a reversal phenotype (n=4) experienced HRQoL similar 
to the general population, whereas the males with a history of prior cryptorchidism 
and/or micropenis (n=14) reported significantly lower 15D scores in the dimension 
of sexual activity (P < 0.01). Interestingly, the age at diagnosis correlated 
negatively with the 15D score (rs= -0.4, P < 0.05) and the dimension of depression 





Figure 11. Health-related quality of life assessed with the 15D instrument in 
males with CHH. A lower 15D value indicates a more severely affected 
dimension. * P < 0.05 (Modified from V). 
 
 
Eight patients with CHH had been diagnosed with depression, bipolar disease 
or anxiety disorder, and all of them were on antidepressants or anxiety medication. 
The subjects who received antidepressants or anxiety medication had lower 15D 
score and the scores in the dimensions of depression, distress, and usual 
activities than those without medication (P < 0.05). Co-morbidities appeared not 
to influence on HRQoL, since the patients with or without co-morbidities reported 
similar 15D scores (P = NS). 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The exact mechanisms that trigger the onset of puberty are inadequately 
understood. Similarly, the influence of sex steroids on growth during infancy is 
unknown. This study addressed these issues by showing for the first time that 
pubertal activation of the HPG axis is preceded by a decline in serum MKRN3 
levels, and that the boys with congenital sex steroid deficiency experience a 
reduced growth velocity during the first six months of life. Additionally, the reduced 
growth velocity may serve as a non-reproductive cue to detect boys with CHH. 
The timely diagnosis of CHH is emphasized by the finding that adult males with 
CHH experience an impaired HRQoL which associated with the later age of 
diagnosis. The results also show that a careful review of medical history and 
physical examination are effective clinical tools in the differential diagnosis of DP, 
particularly in distinguishing patients with CHH from those with CDGP. The 
importance of these results is discussed in detail in the subsequent section. 
1. Circulating MKRN3 levels in boys before the clinical onset 
puberty 
In boys, circulating MKRN3 levels declined before the onset of puberty, and the 
decrease was more rapid during prepuberty than after the onset of puberty. 
Further, the rate of decline in MKRN3 levels associated negatively with the clinical 
and the biochemical markers of HPG axis activity. Interestingly, after our results 
were published, a Danish group reported serum MKRN3 levels in healthy 
peripubertal boys (Busch et al. 2016). The study confirmed our findings that in 
boys MKRN3 levels decline during peripuberty (Busch et al. 2016). Conversely, 
Busch et al. reported no correlation between serum MKRN3 levels and the levels 
of LH, inhibin B or testosterone (Busch et al. 2016). This difference may be 
explained by the fact that circulating MKRN3 exhibited a large inter-individual 
variation which could have diluted the possible correlations between MKRN3 and 
biomarkers of puberty (I, (Busch et al. 2016) ). On the other hand, 16 of our boys 
with ISS were treated with an AI, which enhances the secretion of gonadotropins 
and testosterone by removing the negative feedback of estrogen on the HPG axis 
(Figure 1A). This may have resulted in the strengthening of the reciprocal 
changes between the MKRN3 levels and the biochemical markers of puberty. 
Altogether, the decline in MKRN3 levels appear to precede the onset of puberty. 
The exact mechanisms of MKRN3 in the control of puberty are unclear, albeit 
it is expressed ubiquitously in human tissue, especially in the testis, (Uhlen et al. 
2015). MKRN3 is located at the Prader-Willi and Angelman syndrome critical 
region in chromosome 15 (Jong et al. 1999). MKRN3 is suggested to participate 
in protein ubiquitination, in which proteins are tagged with an ubiquitin and then 
send to proteasome and degraded into small peptides (Rock et al. 1994). In this 
process, MKRN3 and other ring zinc-finger proteins tag the target proteins by 
mediating the transfer on ubiquitin (Schwabe & Klug 1994, Deshaies & Joazeiro 
2009). In mice, Mkrn3 is expressed in the ARC which regulates the activity of 
GnRH neurons, and the decrease in hypothalamic Mkrn3 occurs right before the 
onset of puberty (Abreu et al. 2013). In support of this, the zinc-finger protein 
family appears to control the epigenetic repression of puberty in primates, and the 
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expression of several zinc-finger protein genes is down-regulated at the time of 
the HPG reactivation (Lomniczi et al. 2015). The levels of MKRN3 in adolescents 
decline months and yrs before the onset of puberty, which suggests that MKRN3 
serves as a transmitter of inhibitory signals to the GnRH neurons (I, (Abreu et al. 
2013, Hagen et al. 2015, Busch et al. 2016) ). The temporal correlation between 
the decline in circulating MKRN3, together with the activation of the HPG axis, and 
the result that MKRN3 levels of boys decline faster before than after the onset of 
puberty, pinpoints the loosening of the MKRN3 brake to the prepubertal time. The 
observed inter-individual variation in MKRN3 levels, and the finding that the 
decline in MKRN3 levels continues with a slower pace throughout the puberty (I, 
(Busch et al. 2016) ), suggest the presence of individual MKRN3 threshold for the 
release of the MKRN3 brake. However, it is noteworthy that MKRN3 is likely not 
the only regulator of puberty onset, and its functions may be compensated by 
other factors. Interestingly, circulating MKRN3 levels appear to differ between 
sexes (Hagen et al. 2015, Busch et al. 2016), since MKRN3 levels are higher in 
girls and decline steadier as compared to the biphasic change observed in boys 
(I, (Hagen et al. 2015, Busch et al. 2016) ). Similarly, CPP is more common in girls 
than boys ((Abreu et al. 2013, Macedo et al. 2014), and the boys with CPP and a 
paternally inherited MKRN3 mutation experience a smaller decline in the age of 
puberty onset than the corresponding girls (reviewed in Simon et al. 2015). Thus, 
the role of MKRN3 in the inhibition of GnRH secretion appear to be more profound 
in girls. 
The absence of evidence describing the relationship between estrogen and 
MKRN3 is striking. Hagen et al. reported longitudinal MKRN3 changes in girls, but 
they did not find correlation between circulating MKRN3 and estradiol levels 
(Hagen et al. 2015). In contrast, we found that the boys treated with an AI had a 
slower rate of decline in MKRN3 levels, which suggests that estrogen influences 
MKRN3 secretion and supports a role of estrogen as a factor that promotes the 
loosening of the central restrain on the HPG axis (Flor-Cisneros et al. 2004, Cui 
et al. 2015). To this end, there appears to be a negative association between a 
measure of childhood estrogen exposure – bone age – and the age at the onset 
of puberty (Flor-Cisneros et al. 2004). Boys with chronic diseases that have 
delayed bone maturation, such as malnutrition or GH deficiency, present delayed 
reactivation of the HPG axis, whereas patients with condition that accelerate bone 
development, such as CAH, also enter puberty at an earlier age (Flor-Cisneros et 
al. 2004). These findings beg the question if circulating MKRN3 could be used in 
the differential diagnosis of DP. We found that the boys with late puberty 
experienced a smaller decline in MKRN3 levels than those with normal timing of 
puberty, and Hagen et al. reported lower levels of MKRN3 in early maturing girls 
(Hagen et al. 2015). However, serum MKRN3 levels in boys are similar to those 
reported in healthy men and men with CHH (Varimo et al. 2016). The effectiveness 
of serum MKRN3 in detecting disorders of pubertal development should be 
investigated in a prospective study including adolescents with CDGP, CPP, and 
CHH. 
The studies on circulating MKRN3 levels in humans published so far have 
shown a large inter-individual variation I, (Hagen et al. 2015, Busch et al. 2016). 
The levels of MKRN3 differ between laboratories (Hagen et al. 2015, Busch et al. 
2016, Varimo et al. 2016), albeit all the studies in humans have used the same 
commercial ELISA kit. Consequently, the use of MKRN3 ELISA kit needs to be 
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validated and replicated in larger cohorts. Additionally, international age- and sex-
specific reference standards for circulating MKRN3 are required.  
2. The diagnoses and predictors of DP 
A wide spectrum of different diagnoses were found to cause DP, of which CDGP 
was the most common cause in both sexes. The results are largely consistent with 
the findings of previous studies on DP (Sedlmeyer & Palmert 2002, Reindollar & 
McDonough 1981, Lawaetz et al. 2015, Toublanc, Roger & Chaussain 1991). In 
our series, however, the frequency of CDGP was higher, whereas the proportions 
of PHH and FHH were lower than reported in the most comprehensive series of 
DP published to date (Sedlmeyer & Palmert 2002). The latter difference may be 
explained by the fact that the study of Sedlmeyer et al., as well as most of the 
previous studies on DP, have been conducted in tertiary centers which may have 
increased the frequency of rare conditions that underlie DP such as PHH 
(Sedlmeyer & Palmert 2002, Reindollar & McDonough 1981, Lawaetz et al. 2015). 
This may have resulted in a higher proportion of patients with PHH (Sedlmeyer & 
Palmert 2002). A recent review, which included a small retrospective evaluation 
of patients investigated for DP during a two-year period in an academic center, 
reported a frequency of CDGP (70%) very similar to ours (Abitbol, Zborovski &  
Palmert 2016). Moreover, the authors of the review speculate that the true number 
of CDGP patients is probably even higher due to the fact that previous studies 
have included patients evaluated in a specialized tertiary center (Abitbol, 
Zborovski & Palmert 2016). Indeed, the high proportion of CDGP in our series 
might be explained by the patient referral. Our tertiary center outpatient clinic 
receives direct referrals from general practitioners who evaluate children for 
pubertal disorders in the Helsinki area school health care. Thus, our series 
probably resembles the general pediatric population well. 
In our series, the proportion of Hyper H was half of the frequency reported 
before (Sedlmeyer & Palmert 2002). Interestingly, TS was found in 27% of girls 
with Hyper H, which is a low proportion since TS is reported to affect 1:2500 live 
births (Stochholm et al. 2006), but a frequency that is consistent with the study of 
Sedlmeyer et al. (Sedlmeyer & Palmert 2002). Hence, this suggests that patients 
with TS are diagnosed earlier than in adolescence with clinical features other than 
DP, such as reduced growth velocity and short stature. Surprisingly, the proportion 
of girls with idiopathic ovarian dysfunction was high in our center. The girls tested 
negative for the Finnish-type FSH receptor gene mutation which causes 29% of 
cases with primary ovarian failure in Finland (Aittomaki et al. 1995, Aittomaki 
1994). Since these girls had normal anatomy of the reproductive organs and no 
ovarian auto-antibodies, this suggests that they may harbor a novel gene defect 
which results in ovarian dysfunction that should be further studied. 
Physicians in school healthcare, pediatricians, and pediatric subspecialists 
evaluate patients with DP. Performing a wide range of diagnostic tests at the initial 
evaluation may not always be necessary (Palmert & Dunkel 2012, Abitbol, 
Zborovski & Palmert 2016). Our results on the outcome predictors of DP 
emphasize the importance of a careful review of medical history. A history of 
cryptorchidism was a risk factor for CHH, whereas normally descended testes 
decreased the risk of permanent hypogonadism. The OR of normally descended 
testes decreased when it was combined with the knowledge of pubertal timing in 
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the patient’s family. Thus, a boy with normally descended testes who reported DP 
in a close relative, was likely to have CDGP or FHH as the cause of DP. Further, 
if these boys do not report any neurological or visual symptoms or findings, the 
second-line investigations of DP, if needed at all, can be focused on excluding 
chronic diseases that delay puberty (i.e. FHH) and to those fail to show 
spontaneous pubertal development during follow-up.  
Although the annual growth velocity less than 3 cm was associated with the 
increased frequency of FHH in boys, the further analyses of growth velocity failed 
to reveal any effective threshold for identifying patients with a pathological 
underlying cause for DP. However, this may result from the fact that our series 
included only a few patients with a hypothalamic or pituitary lesion. In girls with 
DP, the previously reported growth velocity cutoff level (3 cm/yr) performs 
inadequeately (Palmert & Dunkel 2012). Growth velocity did not prove to be useful 
in pinpointing the patients who require a brain MRI either. This is important since 
the patients with lesions in the hypothalamic or pituitary area of CNS show 
reduced growth velocity long before any neuro-ophthalmic symptoms or signs of 
delayed puberty are present (Taylor et al. 2012). The results of the clinical and the 
biochemical predictors of DP are summarized in Table 9 (Table 9). 
 
Table 9. Clinical and hormonal markers which suggest the diagnostic category of 
delayed puberty (II).  
Predictor CHH/PHH CDGP FHH 
History of cryptorchidism +++   
Heigh velocity < 3 cm/yr   ++ 
Small testicles (< 1.1 mL) ++ + + 
LH < 0.5 IU/L ++ + + 
FSH < 1.2 IU/L ++ + + 
Inhibin B < 60 ng/L ++ + + 
GnRH-induced LH < 4.3 IU/L ++ + + 
TV < 1 mL and inhibin B < 50 ng/L +++ +   
PHH, permanent hypogonadotropic hypogonadism; CHH, congenital hypogonadotropic 
hypogonadism; CDGP, constitutional delay of growth and puberty; FHH, functional 
hypogonadotropic hypogonadism; TV, testicular volume. 
 
The differential diagnosis between CHH and CDGP is extremely challenging, 
and new evidence-based clinical parameters that could aid in this process are 
warranted (Harrington & Palmert 2012). Testis size, measured with a ruler, inhibin 
B and GnRH-induced LH levels emerged as the most effective markers to 
discriminate between the prepubertal boys with CHH and those with CDGP. After 
testis size was combined with inhibin B or GnRH-induced LH levels, a slightly 
improved discriminatory power was reached. Sertoli cell markers, GnRH and hCG 
stimulation tests, and their combinations have been investigated before in order 
to find an effective diagnostic parameter that would identify patients with CHH. 
Unfortunately, none of the tests show a complete accuracy (Harrington & Palmert 
2012, Segal et al. 2009, Dunkel et al. 1985, Coutant et al. 2010, Adan et al. 2010, 
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Grinspon et al. 2010). We addressed the dilemma from a new viewpoint, and 
developed a testis size and inhibin B-based clinical prediction tool to estimate the 
risk of CHH in a prepubertal boy with DP. In the model, subject’s inhibin B value 
is classified in one of the three inhibin B categories obtained from QC 
measurements instead of using a single inhibin B cutoff level (Coutant et al. 2010, 
Rohayem et al. 2015). This is crucial since we know that the performance of 
inhibin B assay is not optimal at low analyte levels (Kalra et al. 2010). The 
prediction model may serve as an additional support for the clinician pondering 
between CHH and CDGP.  
3. The influence of sex steroid deficiency on growth during 
minipuberty, childhood and adolescence 
We depicted the growth charts of patients with CHH from birth to adult height. 
During minipuberty, the boys with CHH experienced a transient deflection in the 
length SDS, whereas a similar decrease was not evident in girls. The findings 
suggest that the minipubertal length deflection is a new non-reproductive feature 
of CHH, and that androgens modulate growth during the first six months of life. 
Importantly, we found that the decline in length SDS was more profound in boys 
with signs of a severe GnRH deficiency (i.e. a history of cryptorchidism or 
micropenis). In line with our finding, minipubertal testosterone levels in healthy 
boys correlate positively with penile growth and length velocity (Boas et al. 2006, 
Kiviranta et al. 2016). Boys have a more rapid growth velocity than girls during the 
first six months of life (Kiviranta et al. 2016), which may be explained by a sex-
difference in hormonal milieu. During minipuberty, testosterone levels rise rapidly 
in boys, whereas in girls estradiol levels increase, but fluctuate and decline more 
slowly (reviewed in Kuiri-Hanninen, Sankilampi & Dunkel 2014). Thus, it would be 
tempting to postulate that, in boys, the growth during early infancy is more 
sensitive to the influence of sex-steroids. Nevertheless, the importance of nutrition 
in growth during early infancy cannot be excluded. During the first year of life, liver 
IGF-1 secretion is nutrition-dependent and carbohydrate-containing diet 
associates positively with growth rate (Socha et al. 2011, Chellakooty et al. 2006). 
The information on the nutrition during minipuberty was not available in our 
patients due to the retrospective setting. The study included the growth 
measurements of only six girls with CHH, thus, some changes in growth may have 
escaped detection. However, the findings in healthy boys treated with 
testosterone for micropenis, strongly support the role of androgens in the 
modulation of growth during early infancy (Landier, Chaussain & Job 1984, 
Guthrie, Smith & Graham 1973). 
Both the boys and the girls with CHH experienced a relatively normal childhood 
growth, which is consistent with the sparse growth data of CHH patients published 
before (Van Dop et al. 1987, Raboch & Reisenauer 1976, Dickerman, Cohen & 
Laron 1992, Kaushanski & Laron 1979). The decreased growth rate observed in 
patients with CHH at the age of 4 to 7 yrs supports the view that estrogen regulates 
bone and linear growth already during prepuberty (Cutler 1997, Janner, Fluck & 
Mullis 2012). In both sexes, the height SDS reached its nadir right before the 
induction of puberty. 
The initiation of sex steroid treatment recovered the linear growth, since the 
adult heights were similar to MPHs. In contrast, previous studies have reported 
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that patients with CHH usually exceed their MPHs and adult heights of the general 
population due to the delayed fusion of the epiphyseal plates (Raboch & 
Reisenauer 1976, Dickerman, Cohen & Laron 1992, Uriarte et al. 1992). This 
difference may be explained by the findings that the average age of puberty 
induction was lower in our study than reported before (Raboch & Reisenauer 
1976, Dickerman, Cohen & Laron 1992, Uriarte et al. 1992), and the secular trend 
in the age of puberty induction in Finland had declined from the 1970s onwards. 
Since the cohort extended as far as the 1970s, there were patients who received 
very high doses of testosterone to induce pubertal maturation at the expense of 
losing some of their growth potential. Indeed, we found that the cumulative dosage 
of testosterone during the first treatment year correlated negatively with the adult 
height. Altogether, these results underline the importance of timely diagnosis and 
treatment of CHH. 
The influence of different genotypes to linear growth remain speculative. We 
found no association between molecular genetic diagnosis and growth during 
infancy, childhood or adult height. The patients with CHH and a verified gene 
mutation experienced weight gain during infancy, childhood, and adolescence, 
which was similar to those without gene mutations. In fact, the only difference 
found was that the boys with ANOS1 were shorter than those with FGFR1 
mutations at birth. The further investigation of this genotype-growth correlation is 
hindered by the absence of anos1 mouse model. However, since an excess 
androgen milieu during fetal life results in a higher birth length (Balsamo et al. 
2006) and ANOS1 usually relates to a more severe gonadotropin and sex steroid 
deficiency (Costa-Barbosa et al. 2013), it could be speculated that the lower birth 
length in patients with ANOS1 stems from the altered intrauterine sex steroid 
milieu. 
4. Health-related quality of life in males with CHH 
Congenital sex steroid deficiency associated with an impaired HRQoL in 
adulthood. Specifically, the males with CHH reported lower HRQoL scores than 
the age- and sex-matched sample of general population, and the dimensions 
mostly affected were depression and distress. This is in agreement with the two 
previous studies on HRQoL in patients with CHH (Aydogan et al. 2012, Shiraishi, 
Oka & Matsuyama 2014), and it supports the view that congenital sex steroid 
deficiency causes long-term consequences on general well-being in adulthood. 
Remarkably, the HRQoL dimensions affected in our cohort were similar to those 
reported in the study by Aydogan et al. (Aydogan et al. 2012). In the previous 
studies, hormone replacement therapy improved significantly several domains of 
HRQoL, especially the dimensions related to psychological well-being (Aydogan 
et al. 2012, Shiraishi, Oka & Matsuyama 2014). This supports a causative 
relationship between long-term testosterone deficiency and impaired HRQoL. In 
contrast, we found no association between the adequate testosterone 
replacement therapy during adulthood and HRQoL scores. The results may be 
explained by the cross-sectional design of our study, or by the fact that the primary 
effects of delayed physical changes of puberty occur already during adolescence 
and early adulthood, before the onset of testosterone therapy, and paves the way 
for the long-lasting psychosocial consequences. In support of this, we found a 
negative correlation between the age at diagnosis and the HRQoL scores, and 
that CHH men with a history genital anomalies (micropenis and/or cryptorchidism) 
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have experienced a lower HRQoL in the dimension of sexual activity. A recent 
survey, which included males with CHH, identified negative psychological effects 
attributed to late diagnosis of CHH (Dwyer et al. 2014). In particular, the patients 
expressed anxiety and depression, body image concerns, low self-esteem, and a 
sensation of being left-behind as their peers developed into adult bodies (Dwyer 
et al. 2014). Although the data are limited, these findings support the concept that 
the timely diagnosis of males with CHH is vital for the prevention of long-term 
psychological consequences. 
5. Future perspectives  
The mechanisms that trigger the onset of puberty remain elusive. The discovery 
of MKRN3 as one of the gatekeepers of pubertal onset, has focused the research 
on finding novel genes that contribute to the timing of puberty. Similarly, the exact 
role of extrogen in this process is unknown. At the same time, clinicians who 
evaluate adolescents with DP face not only the problem of identifying patients with 
pathological underlying cause, but also selecting right patients for the second-line 
investigations. Thus, the need for new evidence-based clinical tools to aid in this 
process is evident. 
Late puberty can cause significant psychosocial burden to adolescents, 
especially to boys, and even limit their social integration with peers (Gross & Duke 
1980). Currently, the boys with CDGP have two options for the management of 
late puberty in Finland: watchful waiting and expediting pubertal changes with a 
low-dose intramuscular testosterone. The dose and the treatment period of low-
dose testosterone vary (Ambler 2009). Moreover, intra-muscular testosterone 
appears to suppress rather than activate the HPG axis, which questions its role 
as a standard of care for CDGP (Palmert & Dunkel 2012, Ambler 2009). 
Interestingly, the studies in boys with ISS have shown that AIs stimulate 
endogenous gonadotropin and testosterone production, and augment the 
progression of puberty (Dunkel & Wickman 2001, Hero, Norjavaara & Dunkel 
2005). In an attempt to compare AIs to the current standard of care in the DP,  this 
needs to be evaluated in a randomized-controlled setting, such as the one 
currently ongoing in five Finnish hospitals. 
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